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Abstract
Chronic stress is associated with elevated levels of sympathetic neurotransmitter
release and immunosuppression. A growing body of evidence suggests that stress-related
factors may contribute to the initiation, development and progression of breast cancer.
Neuropeptide Y (NPY) has recently been determined as such a factor, however few
investigations have addressed the functional effects of NPY on breast cells and tumors.
Thus, the overall objective of this thesis was to elucidate the mechanisms by which NPY
may contribute to the disease. Using the 4T1 murine breast cancer model, we began by first
characterizing NPY receptor expression in cancer cells and tumors. Y1R, Y2R and Y5R’s
were expressed in 4T1 cells and tumors. In vitro assays were then conducted to determine
the effects of NPY receptor activation on 4T1 cell proliferation and migration. NPY treatment
of 4T1 cells stimulated Y5R mediated increases in proliferation, whereas, NPY increased
chemotaxis through Y2R and Y5R activation. We then tested whether NPY could function as
an angiogenic factor by augmenting expression and secretion of the pro-angiogenic factor
VEGF from breast cancer cells. We found that NPY functioned as a paracrine system within
4T1 and MDA-MB-231 cancer cells to promote angiogenesis, signaling to increase
expression and release of VEGF through Y5R activation. These findings served as a
motivation for our final study where we sought to develop an in vivo model in which the
components of NPY system (i.e., nerves, ligands and receptors) could be functionally
studied. We first demonstrated sympathetic neural innervation and NPY expression in 4T1
tumors. Secondly, when tumor sympathetic neural innervation was attenuated (via chemical
sympathectomy), we observed a significant decrease in tumor growth and vascular
development. Furthermore, we observed that treatment with a Y5R antagonist significantly
attenuated tumor growth. Finally, we established a protocol for intravital microscopy imaging
of tumoral vasculature. Overall, this dissertation provides: 1) evidence that NPY elicits
iii

proliferative, migratory and angiogenic effects on breast cancer cells, 2) an in vivo model for
functional studies examining the role of sympathetic nerves, neurotransmitters, cancer cells
and blood vessels, and 3) highlights the Y5R as a potential therapeutic target.

Keywords: neuropeptide Y, sympathetic nervous system, breast cancer, 4T1 murine breast
cancer, proliferation, chemotaxis, angiogenesis, Y1-receptor, Y2- receptor, Y5-receptor
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Chapter 1

1

Introduction

1.1 General Introduction
Breast cancer is the most frequently diagnosed cancer among females, affecting
thousands of women each year. In 2012 an estimated 22,700 will be diagnosed, and
5,100 will die from breast cancer in Canada (Society, 2012) Death rates have declined
significantly over the past thirty years due to extensive research, as well as more
frequent and advanced breast screening programs in Canada. Nonetheless, many of the
underlying mechanisms that drive the progression of this disease remain to be
understood.
Stress has long been thought to be associated with the development of and
progression of cancer. Epidemiological studies have correlated elevated stress with poor
prognosis and/or survival in cancer patients (Ben-Eliyahu, 2003). From a physiological
context, daily stressors (e.g., physical, psychological, and/or physiological) are known to
cause an activation of the sympathetic nervous system (SNS) or “Fight or Flight”
response. The SNS responds rapidly through increased neural activation, which
releases the neurotransmitters norepinephrine (NE), neuropeptide Y (NPY), and
adenosine triphosphate (ATP) to act on associated receptors in the heart, peripheral
vasculature and other organs. Acutely, this neural response is essential to regulating
cardiovascular and immune function, and maintaining homeostatic balance. However,
chronically elevated SNS activity observed during stress can be problematic in a
pathologies such as cancer. Tissues such as the breast, that are densely innervated by
sympathetic nerves, may become exposed to heightened levels of NE, NPY, and ATP,
thus potentially stimulating deleterious mitogenic, chemotaxic and angiogenic effects on
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cancer development and progression (Cole & Sood, 2012; Ruscica, Dozio, Motta, &
Magni, 2007). Interestingly, women with family histories of breast cancer have been
reported to have greater sympathetic neurotransmitter release (measured in urine
samples) in response to daily stressors (James, Berge-Landry Hv, Valdimarsdottir,
Montgomery, & Bovbjerg, 2004).
Sympathetically mediated immunosuppression was initially postulated as the
mechanism linking stress to cancer progression. The immune system is intimately
regulated by the SNS through innervation of the bone marrow, thymus, spleen and
lymph nodes (Bellinger, et al., 2008; Elenkov, Wilder, Chrousos, & Vizi, 2000; Levite,
2000). Acute sympathetic activation can promote immune responses such as
inflammation; however, past studies have also shown that elevated levels of
norepinephrine can suppress lymphocyte functions such as T-cell proliferation and
antigen presentation (Inbar, et al., 2011; Shakhar & Ben-Eliyahu, 1998). As such,
heightened sympathetic neurotransmitter release has been associated with a
suppressed immune response during primary tumor development and metastasis.
Recent studies have demonstrated that sympathetic neurotransmitters (NE and
NPY) may also have direct effects on cancerous cells (Medeiros, et al., 2012; Sheriff, et
al., 2010; Thaker, et al., 2006). NE activating β-adrenergic receptors has been shown to
promote cell growth, stimulate tumor angiogenesis and increase the incidence of
metastasis in breast, prostate and ovarian cancers (Palm, et al., 2006; Sloan, et al.,
2010; Thaker, et al., 2006). The functional impact of NPY on cancer cells has been a
question of growing interest. NPY functions by activating a group of six G proteincoupled receptors (Y1R-Y6R) of which the Y1R, Y2R and Y5R are most abundantly
expressed in humans, and have been most extensively studied. NPY receptors have
been reported in several types of cancer, including neural crest tumors (i.e.,
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neuroblastomas and pheochromocytomas) and epithelial malignancies such as ovarian,
prostate and breast cancer (Kitlinska, et al., 2005; Kogner, Bjork, & Theodorsson, 1993;
Korner & Reubi, 2008; Korner, Waser, & Reubi, 2004; Magni & Motta, 2001; Reubi,
Gugger, Waser, & Schaer, 2001). Activation of NPY receptors has been reported to
have

receptor

subtype

and

cancer-specific

responses.

Limited studies

have

demonstrated that NPY may cause proliferation or apoptosis, migration, and
angiogenesis in different types of cancer. It has been suggested that NPY receptor
activation may be involved in breast cancer progression by stimulating proliferation of
breast cancer cells, and promoting angiogenesis (Korner & Reubi, 2007), however these
postulates have yet to be confirmed in vivo.
Human xenografts in immunocompromised mice are commonly used to study
primary tumor growth and metastasis. Syngeneic mouse models provide an
immunocompetent model in which tumor cell-host interactions and metastatic patterns
parallel those observed in cancer patients (Prewett, et al., 1999). The 4T1 murine
mammary cancer cell line is a well-established model of breast cancer that been used
extensively to study anti-metastatic and anti-angiogenic therapies in syngeneic models
(Lin, et al., 1998; Prewett, et al., 1999). However, to date, the components of the NPY
system (nerves, ligand and receptors), and/or the functional response of NPY have yet
to be characterized in any sygeneic breast cancer model.

1.2

4T1 Breast Cancer Model

The 4T1 cell line originated from a spontaneously arising BALB/c mammary tumor
(Pulaski & Ostrand-Rosenberg, 2001). It is a highly tumorigenic and invasive cell line
that can spontaneously metastasize from the primary orthotopic mammary tumor to
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multiple secondary sites such as the lymph nodes, lungs, liver, blood, brain and bone
(Pulaski & Ostrand-Rosenberg, 2001; Tao, Fang, Alroy, & Sahagian, 2008).
Orthotopically implanted 4T1 tumors grow rapidly, and will metastasize from the primary
site over a period of 3-6 weeks. Given the rapid and efficient metastatic pattern that has
been observed with the 4T1 model, it has become a commonly used model in the study
of metastatic progression of breast cancer in humans (Pulaski & Ostrand-Rosenberg,
2001; Tao, et al., 2008). Moreover, since it is of a syngeneic cell line in BALB/c mice,
tumor growth and metastasis can be studied in the presence of an intact immune
system, and as such, this mouse model closely parallels the human condition.

1.2.1

Sympathetic Neural Transmission
The SNS is a branch of the autonomic nervous system, which innervates the

heart, vasculature and viscera (Robertson, 2004). It is the body’s primary neural
responder to acute internal or external stresses by increasing its neurotransmitter
release centrally (i.e., viscera) and to the peripheral vasculature (Robertson, 2004).
Sympathetic nerve fibers originate in the lateral horns of the thoracic and lumbar spinal
regions (T1-L2) (Robertson, 2004). Preganglionic myelinated fibers branch off the spine
as white rami, which then enter the sympathetic ganglia. In the ganglia presynpatic
neurons synapse with postganglionic neurons (Robertson, 2004). Neural transmission
between pre and post fibers occurs by the release of acetylcholine (ACh) from
preganglionic fibers, which then binds to nicotinic receptors of postganglionic fibers
(Robertson, 2004). Sympathetic transmission concludes with the postganglionic release
of sympathetic neurotransmitters: NE, NPY, ATP, met-enkephalin, substance P,
bombesin and dopamine, of which NE, NPY and ATP predominate (Robertson, 2004).
These neurotransmitters will then bind to their respective receptors located on the target
tissue. The breast receives sympathetic innervation from nerves arising from the lateral
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and anterior cutaneous branches of the second to sixth intercostal nerves (Fischer &
Bland, 2007). These nerves provide a constant supply of sympathetic neurotransmitters
to the mammary gland, smooth muscle of the areola, skin and breast blood vessels
(Fischer & Bland, 2007)

1.2.2

Catecholamines

Catecholamines are amines that are structurally characterized by a benzene ring,
two hydroxyl groups, an intermediate ethyl chain, and a terminal amine group. In
humans the most abundantly synthesized and released are epinephrine (EP), NE and
dopamine. Chromaffin cells of the adrenal medulla produce EP and NE, peripheral
postganglionic neurons synthesize NE, and dopamine is found in the central nervous
system, functioning as a neurotransmitter in the brainstem. In the periphery, the uptake
of L-tyrosine by postsynaptic nerve terminals is the first step in catecholamine synthesis
(Nagatsu,

Levitt,

&

Udenfriend,

1964).

L-tyrosine

is

then

converted

to

L-

dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH). This
conversion represents the rate-limiting step in the biosynthesis of catecholamines
(Udenfriend, 1966). As such, the production of NE acts to inhibit the production of TH via
a negative feedback reaction (Nagatsu, et al., 1964), whereas a stress induced increase
in sympathetic nerve activity will cause an increase in TH (Wong & Tank, 2007). Laromatic-amino-acid decarboxylase (L-AADC) then catalyzes the conversion of L-DOPA
to dopamine. In peripheral nerve terminals and chromaffin cells, Dopamine-βhydroxylase (DBH) localized in large dense-core vesicles, converts dopamine to NE,
which then remains in the synaptic vesicles until exocytosis occurs and they are
released into the synaptic cleft.
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1.3

Neuropeptide Y

Until recently, only the effects of NE on cancer progression had been examined.
Accumulating data has now illustrated functional implications of NPY and its respective
receptors to the progression of this disease. NPY is the most abundantly expressed
peptide of the pancreatic polypeptide family in mammalian systems, exhibiting
pleiotropic actions throughout the body. The 36-amino acid peptide is most widely
expressed in the central and peripheral nervous systems, playing major roles in
cognitive function, feeding behavior and cardiovascular regulation. NPY is co-stored with
NE within peripheral sympathetic nerves that innervate vascular smooth muscle
(Edvinsson, Emson, McCulloch, Tatemoto, & Uddman, 1983), heart (Gu, et al., 1983),
gut (Gu, et al., 1983), liver (Taborsky, Beltramini, Brown, Veith, & Kowalyk, 1994),
pancreas (Sundler, Moghimzadeh, Hakanson, Ekelund, & Emson, 1983), thyroid gland
(Grunditz, Hakanson, Rerup, Sundler, & Uddman, 1984), respiratory tract (Sheppard,
Polak, Allen, & Bloom, 1984), and eye (Terenghi, et al., 1983) tissues. NPY is also found
in the adrenal glands (de Quidt & Emson, 1986; Majane, Alho, Kataoka, Lee, & Yang,
1985) and is secreted by neural crest tumors such as neuroblastomas and
pheochromocytomas (Grouzmann, Comoy, & Bohuon, 1989).
Tatemoto et al., (Tatemoto, Carlquist, & Mutt, 1982) first isolated NPY from the
porcine brain, and its name was attributed to the presence of a tyrosine at the N- and Ctermini of the complete peptide. NPY is synthesized from the 97-amino acid precursor
pre-pro-neuropeptide Y. Four posttranslational reactions are required to form the active
NPY molecule (Higuchi, Costa, & Yang, 1988). Prohormone convertase 1/3 (PC1/3)
break down proNPY at the paired basic site Lys38–Arg39, thereby releasing the 30 amino
acid C-flanking peptide of NPY and NPY1-39 (Alfalah & Michel, 2004). NPY1-39 is further
processed by a carboxypeptidase-like enzyme, leading to NPY1-37, which thereafter
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becomes

amidated

at

its

C-terminal

end

by

peptidyl-glycine-α-amidating

monooxygenase, cleaving off another amino acid. The final biologically active fragment
(NPY1-36) is referred to as NPY.

1.3.1

NPY receptors
NPY’s effects are mediated by the activation of a group of six Gi/Go-protein-

coupled receptors (Y1, Y2, Y3, Y4, Y5 and Y6 subtypes). The Y1, Y2, Y4, Y5 and Y6
subtypes have been all cloned in rodents and humans (Bard, Walker, Branchek, &
Weinshank, 1995; Eva, Keinanen, Monyer, Seeburg, & Sprengel, 1990; Weinberg, et al.,
1996), however only Y1, Y2, Y4 and Y5 appear to be functional in humans. NPY
receptors have been grouped into subfamilies in which the Y1, Y4 and Y6 subtype make
up the Y1 subfamily, and the Y2 and Y5 subtype each are in their own respective
subfamily (Larhammar & Salaneck, 2004).
Structurally, NPY receptors are seven-transmembrane heterotrimeric G-protein
coupled receptors. Activation of G-protein coupled receptors lead to exchange of GDP
for GTP by inactivated GDP-bound proteins on the Gα subunit, causing its dissociation
from the Gβγ dimer. The active GTP-bound Gα subunit and the Gβγ complex will then
modulate further downstream effects such as the inhibition of adenylate cyclase causing
a decrease in cAMP. Zhu et al., confirmed this effect by blocking this response with
pertussis toxin, supporting that NPY receptors are coupled to heterotrimeric inhibitory
Gi/Go proteins (Zhu, Li, Toews, & Hexum, 1992). Furthermore, NPY stimulated increases
in cAMP cause increases in secondary messengers such as cystolic calcium, which can
increase the activity of other pathways such as the mitogen-activated protein kinase
(MAPK) pathway (Nie & Selbie, 1998).
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1.3.1.1

The Neuropeptide Y Y1-receptor

The Y1 receptor (Y1R) was the first NPY receptor to be cloned, and initially
discovered in the rat brain (Eva et al., 1990). Y1Rs are expressed throughout
organs/tissues in the body, including the viscera, blood vessels and neural tissues (i.e.
nerves and brain) (Korner, et al., 2004; Larhammar, et al., 1992; Matsuda, Brumovsky,
Kopp, Pedrazzini, & Hokfelt, 2002; Mihara, Shigeri, & Fujimoto, 1990; Peaire, Krantis, &
Staines, 1997). Y1R expression has also been reported in several types of endocrine
tumors and epithelial malignancies, such as ovarian, prostate, breast and neural crest
tumors (e.g., pheochromocytoma and paraganglioma) (Korner & Reubi, 2008; Korner, et
al., 2004; Magni & Motta, 2001; Reubi, et al., 2001).
Robust Y1R expression has been reported in several breast cancer tumors and
cell lines. Reubi et al., reported expression of Y1R in 85% of breast tumor biopsy
samples, whereas normal tissues showed little expression (Reubi, et al., 2001). Sherrif
et al., probed several commonly used breast cancer cell lines and reported expression in
MCF7, T47D, MDA MB-231, MDA MB-468, and HS578T cells (Sheriff, et al., 2010). Y1R
expression has also been reported to be associated with estrogen levels in cancer cells,
where estrogen was found to increase Y1 expression in MCF7 cells, which, when
stimulated with Y1R agonists, caused a decrease in estrogen-stimulated cell proliferation
(Amlal, Faroqui, Balasubramaniam, & Sheriff, 2006).
The N-terminus is essential for NPY to activate Y1R, thus the complete NPY1-36
molecule is necessary for NPY to bind to the Y1R. As the N-terminal part of the peptide
is cleaved by membrane-bound peptidases, dipeptidyl peptidase IV (DPPIV or CD26)
and aminopeptidase P (APP), the affinity of the peptide to the Y1R is diminished
(Larhammar et al., 1992). As a result, N-terminally truncated NPY fragments such as
NPY2-36, or NPY3-36 have affinity for Y2R and Y5R, and very little affinity for Y1Rs,
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whereas alterations to the C-terminal residues have little effect on the affinity of the
peptide for the Y1R. Therefore, the enzymatic activity of the aforementioned proteases
may contribute to modulating the ratio in which Y1, Y2 and Y5 receptors are activated in
tumors, and subsequently affect NPY mediated proliferation, migration and/or
angiogenesis.

1.3.1.2

The Neuropeptide Y Y2-receptor

The Y2 receptor (Y2R) was first cloned from SMS-KAN cells and later from
human brain and KAN-TX cells (Gerald, et al., 1995). Localized primarily presynaptically
(Chen, DiMaggio, Han, & Westfall, 1997), Y2R’s have been found to regulate the release
of NPY and other neurotransmitters (Wahlestedt, Edvinsson, Ekblad, & Hakanson, 1985;
Zukowska-Grojec, Karwatowska-Prokopczuk, Fisher, & Ji, 1998). Expression of Y2Rs
has been reported in the vasculature (Zukowska-Grojec, et al., 1998), the intestine
(Rettenbacher & Reubi, 2001), brain (Stanic, et al., 2006) and breast tissue (Reubi, et
al., 2001). Expression of the Y2R has been reported in neural endocrine tumors
(Kitlinska, et al., 2005) and in breast cancer (Reubi, et al., 2001). However, the Y2R was
found to predominate in normal breast tissue, switching to the Y1R subtype in neoplastic
tissue, thus Y2R expressing tumors represented a small cohort of breast tumors.
Y2R activation leads to an inhibition of adenylate cyclase and voltage dependent
Ca2+ channels via Y2R coupled G-proteins. Cleaving of the N-terminus of NPY has little
effect on the binding affinity to the Y2R. NPY fragments such as NPY2-36, NPY3-36 are of
equal affinity to Y2Rs as the complete peptide, whereas, NPY13-36, PYY3-36, NPY22-36 will
bind to Y2R with subnanomolar affinity (Beck-Sickinger & Jung, 1995). On presynaptic
neurons, Y2R has been shown to be autoregulatory, as its activation can inhibit the
release of neuronally derived NPY (Malmstrom, Lundberg, & Weitzberg, 2002).
Activation of Y2Rs on neuroendocrine tumor cells has been reported to stimulate cell
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proliferation (Kitlinska, et al., 2005; Movafagh, Hobson, Spiegel, Kleinman, & Zukowska,
2006) and in endothelial cells shown to promote growth, migration and capillary tube
formation (Movafagh, et al., 2006).

1.3.1.3

The Neuropeptide Y5-Receptor

The NPY Y5 receptor (Y5R) was first cloned in 1996 from mouse genomic DNA
(Weinberg, et al., 1996). Sharing close homology with the Y1R, the Y5R consists of 60%
of the same amino acids as the Y1R (Weinberg et al. 1996). Y5R expression has been
reported throughout the body including gastrointestinal tract (Goumain, Voisin, Lorinet, &
Laburthe, 1998), testis, pancreas, spleen, and skin (Statnick, et al., 1998). Centrally, the
Y5R is expressed in the hypothalamus, cortex and brainstem (Grove, Campbell,
Ffrench-Mullen, Cowley, & Smith, 2000). Growing evidence has demonstrated the
prevalence of Y5Rs in several types of malignancies including colorectal, prostate,
ovarian and breast (Patent no. US2011/0112102 A1). Recently, Y5R expression was
reported in the MCF-7, T47D, MDA MB-231, MDA MB-468, HS578T and BT-549 cell
lines (Sheriff, et al., 2010) (Table 1).
In the CNS, activation of the Y5R has been shown associated with appetite
regulation and circadian cycle (Larhammar & Salaneck, 2004). Activation of Y5Rs on
cardiomyocytes has been reported to promote cell growth/hypertrophy (Pellieux, et al.,
2000). The proliferative potential of Y5R activation has been reported in neuroblastomas
(Kitlinska, et al., 2005) and more recently in BT-549 breast cancer cells (Sheriff 2010).
Activation of the Y5R was shown to stimulate cell growth through increased mitogenactivated protein kinase (MAPK) activity and concomitant with increased extracellular
signal-regulated kinase (ERK 1/2) phosphorylation (Sheriff, et al., 2010). The role of the
Y5R activation on breast cancer tumor progression has yet to be examined clinically or
in an in vivo model.
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Table 1. NPY Y-receptor expression in human breast cancer cell lines. Data adapted
from Sheriff et. al (Sheriff, et al., 2010).
Cell Line

Y1R

Y2R

Y5R

MCF-7

+

-

+

T47D

+

-

+

MDA MB-231

+

-

+

MDA MB-468

+

-

+

HS578T

+

-

+

BT-549

-

-

+

1.3.2

NPY Stimulated Cell Proliferation
NPY has been shown to stimulate proliferation in different vascular tissues

including endothelial and vascular smooth muscle cells (Shigeri & Fujimoto, 1993;
Zukowska-Grojec, et al., 1998), as well as cardiomyocytes (Pellieux, et al., 2000). NPY’s
mitogenic properties are dependent on the presence of the Y1R, Y2R and Y5R.
Activation of one or more of these receptors has been shown to increase DNA synthesis
and cell proliferation in a dose-dependent manner (Shigeri & Fujimoto, 1993). NPY
stimulated proliferation occurs through an increase in mitogen-activated protein kinase
(MAPK) activity, leading to increased extracellular signal-regulated kinase (ERK 1/2)
phosphorylation (Pellieux, et al., 2000; Sheriff, et al., 2010; Zukowska-Grojec, et al.,
1998). This response has been observed in prostate cancer cells (Ruscica, et al., 2006),
neuroblastoma cells and recently in breast cancer cells (Sheriff, et al., 2010).
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1.3.3

NPY Stimulated Chemotaxis
Chemotaxis is defined as the movement of an organism or cell along a chemical

(chemo-attractant) concentration gradient either towards or away from the chemical
stimulus. Chemotactic potential is commonly examined with the use of a Boyden
chamber assay. Originally developed to analyze leukocyte chemotaxis, a Boyden
chamber is composed of two medium-filled compartments separated by a microporous
membrane. Cells placed in the top chamber will migrate through micropores toward a
chemoattractant, which fills the bottom chamber. NPY has been shown to be a
chemoattractant to monocytes, macrophages, and endothelial cells (Straub, et al.,
2000). Limited studies have demonstrated NPY potential to increase cell migration in
different types of cancer cells (Sheriff, et al., 2010) such as breast cancer cells. Drell et
al., (Drell, et al., 2003) reported that sympathetic neurotransmitters met-enkephalin,
substance P, bombesin, dopamine, and norepinephrine had a stimulatory effect on the
migration of the breast cancer cells, but the effects of NPY were not examined.

1.3.4

NPY Stimulated Angiogenesis
Briefly, angiogenesis is the process of new blood vessel formation from pre-

existing vessels. This process occurs minimally under homeostatic conditions, and it is
integral to responses such as wound healing (Knighton, Silver, & Hunt, 1981). During
pathological conditions such as cancer, angiogenic activity also increases to supply a
tumor with new vasculature. In vitro assays have demonstrated NPY’s angiogenic
potential, and, under physiological concentrations, NPY stimulates adhesion, migration,
proliferation and capillary tube formation in human endothelial cells (Movafagh, et al.,
2006; Zukowska-Grojec, et al., 1998). These responses initially thought to be meditated
solely by the Y2R, were later reported to occur bimodally via Y1R, Y2R or Y5R activation
(Movafagh, et al., 2006). In vivo studies have further supported NPY’s angiogenic
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actions through Y2R activation, as Y2R knockdown mice exhibit compromised wound
healing (Ekstrand, et al., 2003; Lee, Grant, Movafagh, & Zukowska, 2003). Moreover,
hypoxia-induced retinal angiogenesis is absent in neonatal Y2 deficient mice (Koulu, et
al., 2004). In the context of breast cancer progression, NPY is postulated to be an
angiogenic factor contributing to new vessel formation during tumor development.
Interestingly, neurotransmitters such as NE can function in a paracrine manner,
stimulating the release of pro-angiogenic factors such as vascular endothelial growth
factor (VEGF) from cancer cells (Madden, Szpunar, & Brown, 2011). Whether NPY can
function through a similar mechanism in breast cancer has yet to be examined.

1.4

Rationale

Investigating the contribution of NPY to breast cancer progression is reasonable
when the following points are considered: 1) sympathetic nerves arising from the lateral
and anterior cutaneous branches of the second to sixth intercostal nerves richly
innervate the human breast. These nerves provide a constant supply of NPY to the
mammary gland, smooth muscle of the areola, skin and breast blood vessels, 2) women
with family histories of breast cancer have elevated sympathetic neurotransmitters
release in response to daily stressors (James, et al., 2004), and 3) NPY receptors are
expressed in several breast cancer cells (Korner & Reubi, 2007). Given the few
investigations examining the role of NPY in breast cancer, the impetus for this thesis
was to characterize the functional impact of NPY in breast cancer and develop an in vivo
breast cancer model in which the effects of NPY could be studied in an immuno-intact
model.
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1.5

Overall Objective

The overall objective of this thesis was to elucidate the impact of the sympathetic
NPY system on breast cancer development and to develop an in vivo model in which it
could be functionally studied.

1.5.1

Specific Objectives

Manuscript 1: Chapter 2
Test for the presence of NPY receptors in the 4T1 model, and determine whether NPY
elicits proliferative and chemotactic effects on 4T1 cells.

Manuscript 2: Chapter 3
Determine the mechanisms of NPY-stimulated angiogenesis in human and murine
breast cancer models.

Manuscript 3: Chapter 4
Develop an in vivo model of breast cancer to allow for the examination of the
components of the sympathetic NPY system.
To address these objectives, experiments conducted within this thesis utilized
several NPY receptor specific agonists and antagonists, summarized in Table 2.
Table 2. NPY receptor agonists and antagonists.

Agonists

Y1R

Y2R

Y5R

NPY

NPY

NPY

[Leu31,Pro34]-NPY

PYY3-36

[cPP1-7,NPY1923,Ala31,Aib32,Gln34]–
hPP

Antagonists

BIBP3226

BII0246

L-152,802
TAC557
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1.6
1.6.1

Thesis Hypotheses
Overall Working Hypothesis

Overall we hypothesize that the NPY system is involved in breast cancer tumor
formation.

1.6.2

Specific Hypotheses

1) We hypothesized that 4T1 cells and tumors express NPY receptors. (Tested in
Chapter 2)
2) We hypothesized that NPY would stimulate proliferation of 4T1 cells and
increase tumor growth. (Tested in Chapter 2 and 4)
3) We hypothesized that NPY would cause an increase in chemotaxis. (Tested in
Chapter 2)
4) We hypothesized that NPY would stimulate an increase in expression and
secretion of VEGF from breast cancer cells, promoting in vitro angiogenesis.
(Tested in Chapter 3)
5) We hypothesized that sympathetic dennervation of the mammary gland would
attenuate tumor growth and vascularity. (Tested in Chapter 4)
6) We hypothesized that treating tumor-bearing mice with the Y5R antagonist
TAC557 would attenuate tumor growth. (Tested in Chapter 4)
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Figure 1.1 Thesis Road Map
Map. In the current thesis we sought to elucidate the impact of
the sympathetic NPY system on the progression of breast cancer.
cancer Studies were
conducted to determine if NPY receptor (YR) activation would stimulate proliferation and
migration of 4T1 cells. Additionally, the effects of YR activation on VEGF expression and
secretion were examined. In vitro findings supported the development of the 4T1 tumor
model in which the components of the NPY system (i.e., nerves, ligand and receptors)
could be functionally studied.
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Chapter 2

2

Neuropeptide Y stimulates proliferation and migration in
the 4T1 breast cancer cell line
Content from this chapter has been in part adapted from “Neuropeptide Y

stimulates proliferation and migration in the 4T1 breast cancer cell line”., by P.J
Medeiros, B.K Al-Khazraji, N.M Novielli, L.M Postovit, A.F Chambers and D.N Jackson.
International Journal of Cancer 2011 Aug 5. doi: 10.1002/ijc.26350.

2.1 Introduction
Recent studies have demonstrated that stress is correlated with increased breast
cancer risk. Chronic stress leads to elevated sympathetic neurotransmitter release (NE
and NPY), which is associated with immunosuppression, and has been positively
correlated with increased incidences of infection and cancer (Antoni, et al., 2006;
Elenkov, Wilder, Chrousos, & Vizi, 2000; Marsland, Bachen, Cohen, Rabin, & Manuck,
2002; McEwen & Stellar, 1993; Tilan & Kitlinska, 2010). Sympathetic nerves arising from
the lateral and anterior cutaneous branches of the second to sixth intercostal nerves
abundantly innervate the human breast, thereby providing a constant supply of
sympathetic ligands to the breast microenvironment. Interestingly, women with family
histories of breast cancer are reported to have greater sympathetic neurotransmitter
release

under

normal

conditions

(James,

Berge-Landry

Hv,

Valdimarsdottir,

Montgomery, & Bovbjerg, 2004). As such, the pathological contributions of these
neurotransmitters to breast cancer development and progression have been a growing
area of investigation.
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In mammalian systems, NPY is the most abundantly expressed peptide of the
pancreatic polypeptide family, exhibiting pleiotropic actions throughout the body. The 36amino acid peptide is most widely expressed in the central and peripheral nervous
systems, playing major roles in cognitive function, feeding behavior and cardiovascular
regulation. NPY activates a group of six NPY G protein-coupled receptors (Y1R-Y6R) of
which the Y1R, Y2R and Y5R are most abundantly expressed in humans, and have
been most extensively studied (Michel, et al., 1998). In addition to regulating several
physiological functions, NPY has been shown to promote proliferation, vascularization
and stimulate migration in several cell types and tissues (Kuo, Abe, & Zukowska, 2007;
Ruscica, Dozio, Motta, & Magni, 2007; Zukowska-Grojec, Karwatowska-Prokopczuk,
Rose, et al., 1998; Zukowska-Grojec, et al., 1993).
NPY Y1R, Y2R and Y5R expression has been reported in several breast cancer
cell lines (Reubi, Gugger, Waser, & Schaer, 2001; Sheriff, et al., 2010). In human
primary breast carcinomas, 85% exhibited Y1R expression, while only 24% expressed
the Y2R subtype (Reubi, et al., 2001). Recently, Y5R expression was found in the MCF7, T47D, MDA MB-231, MDA MB-468, HS578T and BT-549 cell lines (Sheriff, et al.,
2010). Activation of Y5R in BT-549 cells was shown to stimulate cell growth through
increased mitogen-activated protein kinase (MAPK) activity and concomitant with
increased extracellular signal-regulated kinase (ERK 1/2) phosphorylation (Sheriff, et al.,
2010). In contrast, Y1R activation in MCF-7 cells has been reported to inhibit estrogeninduced proliferation (Amlal, Faroqui, Balasubramaniam, & Sheriff, 2006). The Y2R has
also been shown to increase cellular proliferation, however current studies have been
limited to neuroendocrine tumors, which highly express the receptor (Kitlinska, et al.,
2005; Korner & Reubi, 2008).
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The contribution of NPY to the development of metastasis has been a question of
increasing importance. Neuropeptides have been reported to exhibit chemotactic
potency and stimulate migratory activity of immune (Straub, et al., 2000), endothelial
(Movafagh, Hobson, Spiegel, Kleinman, & Zukowska, 2006) and breast cancer cells
(Drell, et al., 2003; Sheriff, et al., 2010). Substance P and bombesin have been
observed to increase migratory activity in MDA MB-468 cells (Drell, et al., 2003) and
more recently NPY stimulation was reported to increase the migration of MDA MB-231
cells through Y5R activation (Sheriff, et al., 2010).
The 4T1 murine mammary cancer cell line is a well-established model of breast
cancer. It has been used extensively to study anti-metastatic and anti-angiogenic
therapies (Lin, et al., 1998; Prewett, et al., 1999), however the effects of NPY on this
breast cancer model have yet to be examined. Therefore, in the current study, using
qPCR, Western blot and immunohistochemical analyses we examined the expression of
Y1R, Y2R and Y5R in 4T1 cells in vitro and in orthotopic tumors. Positive expression for
each of the three receptors led our group to test whether NPY would stimulate
proliferation and/or migration in this model. Using NPY receptor antagonists, we provide
evidence of Y5R mediated proliferation and Y2R and Y5R mediated chemoattraction to
NPY treatment. These data complement and parallel recent findings in human cell lines,
and highlight the 4T1 cell line as a breast cancer model in which the effects of NPY can
be studied in an immuno-intact in vivo model.
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2.2 Materials and Methods
2.2.1

Reagents and Drugs
Fetal bovine serum (FBS), culture media, Hanks Balanced salt solution (HBSS)

and trypsin were purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON,
Canada). RNA isolation was performed using PureZol© (Aurum Total RNA Mini Kit, BioRad Laboratories, Hercules, CA, USA) and cDNA was synthesized using a RT2 FirstStrand cDNA synthesis kit (QIAGEN Inc, Mississauga ON, Canada). Primer pairs
corresponding to target genes for mouse NPY Y1R (Cat no. PPM042483E), NPY Y2R
(Cat no. PPM04278A), NPY Y5R (Cat no. PPM04629A) and GAPDH (Cat no.
PPM02946E) were purchased from QIAGEN (Mississauga, ON, Canada).
Cell lysis buffer (M-PER Mammalian Protein Extraction Reagent), protease and
phosphatase inhibitors (Halt Phosphatase Inhibitor Cocktail) were purchased from
Pierce (Rockford, IL, USA). For Western blot analysis we used primary antibodies
specific to mouse NPY Y1R, Y2R, Y5R (Cat no. NPY1R11-A, NPY2R11-A, NPY5R11-A,
Alpha Diagnostic International, San Antonio, TX, USA), phospho-ERK 1/2 and total ERK
1/2 (Cell Signaling Technology, Inc.). For secondary incubation we used antibody
conjugated to horseradish peroxidase (goat anti-rabbit IgG, Cat no. A0545, Sigma
Aldrich, St Louis, MO, USA). NPY (non-specific YR agonist), Peptide YY (3-36)
(Y2R/Y5R agonist), [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPancreatic Polypeptide
(hPP; Y5R agonist), BIBP3226 (Y1R antagonist), BIIE0246 (Y2R antagonist), and L152,802 (L-152; Y5R antagonist) were from Tocris (Minneapolis, MN, USA). Cell
proliferation was measured by tetrazolium-based assay from Promega (CellTiter 96®
AQueous One Solution, Madison, WI, USA).
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2.2.2

Cell Culture
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan, USA),

were cultivated in high glucose Delbecco’s Minimal Essential Medium (DMEM)
supplemented with 10% sterile FBS. Cells were incubated at 37ºC and 5% carbon
dioxide. At approximately 80% confluency, cells were washed with HBSS and passaged
using 0.25% trypsin-EDTA treatment for dissociation.

2.2.3

Quantitative RT-PCR
Total RNA was isolated from ~5 × 106 4T1 cells using PureZol© following

manufacturer’s protocols. Five micrograms of RNA was reverse-transcribed in a 25µl
reaction. Primer pairs were used to amplify the target genes for mouse NPY Y1R, NPY
Y2R, NPY Y5R and GAPDH.
Relative quantification of target mRNA was performed using SYBR® green
quantitative RT-PCR detection (CFX 96 real-time PCR detection system, Bio-Rad,
Hercules, CA, USA). Twenty-five microliter reactions were conducted with equal
amounts of cDNA templates from each sample (triplicate) according to the
manufacturer’s protocol. The protocol was: 95°C for 10 minutes, 40 cycles at 95°C for 15
seconds, 60°C for 60 seconds. At the end of the protocol, a stepwise increase in
temperature from 65°C to 95°C was performed and dissociation curves were constructed
to ensure purity of PCR products. Data were analyzed with CFX manager software (BioRad, Hercules, CA, USA). Target gene expression was quantified by measuring
threshold cycle. Experiments were repeated three times.
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2.2.4

Orthotopic Tumor Model
Seven female BALB/c mice, purchased from Charles River Laboratories (Saint-

Constant, QC, Canada) at 7-9 weeks of age, were used in the current study. Animals
were housed in the animal care facility at The University of Western Ontario. They were
maintained on Harlan 2018, Teklad Global 18% Protein Rodent Diet and water ad libitum
and kept on a 12 hr light/dark cycle. All experimental procedures were carried out with
the approval of the Council on Animal Care at The University of Western Ontario.
After three passages, 4T1 cells were prepared for injection. Cells were washed
and resuspended in sterile HBSS. The solution was filtered with a 40 µm cell strainer
and cell viability was assessed by trypan blue staining and counting with a
hemocytometer. The cell suspension was diluted to 103 cells/µl for injection.
Animals were anesthetized with isofluorine/oxygen gas mask (2-3% isofluorine,
1 L/min) and hair was removed from the lower abdominal region using commercial hair
remover (Nair®). A sagittal cut (~1 cm) was made at the lower abdomen and skin was
separated from the underlying muscle, to expose the underlying mammary fat pad. One
hundred microliters (105 cells) of cell suspension was carefully injected into the right
inguinal mammary fat pad. Wound clips were then applied to close the skin incision.
Animals were returned to their cage for recovery and wound clips were removed 7 days
later. Animals were then housed in cages without disturbance for 29 days. Twenty-nine
days post-injection, all mice were sacrificed after induction of anesthesia using Ketamine
(100 mg/kg) and Xylazine (25 mg/kg) followed by cervical dislocation. Mammary tumors
were removed from each animal, sectioned in half, one half flash frozen in liquid nitrogen
and the other fixed in 4% paraformaldehyde.
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2.2.5

Western Blot Analysis
Cultured cells from a 25 cm2 flask were washed twice in ice cold HBSS and then

lysed in 500 µl lysis buffer containing protease (104 mM AEBSF, 80 µM aprotinin, 2.1
mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64) and phosphatase
(Halt Phosphatase Inhibitor Cocktail) inhibitors. Cells were scraped and then lysed by
sonication. One hundred milligrams of tumor tissue was immersed in ice-cold lysis buffer
(50 mM Tris, pH 7.5, 150 mM sodium chloride, 5 mM ethylene glycol tetraacetic acid,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and 1% Triton-X 100) and
mechanically homogenized. Cell and tissue lysates were centrifuged for 15 minutes at
14,000 rpm at 4°C. Supernatant was collected and stored at -80°C until protein
concentration was determined.
A Bradford assay (Bradford, 1976) was performed to determine total protein
concentration of samples. Thirty-five micrograms of protein from each sample and a
positive control (brain lysate) were loaded on a 4% to 12% gradient gel and separated
by SDS-PAGE. After electrophoresis, proteins were transferred at a constant voltage to
polyvinylidene fluoride membranes. Membranes were blocked for 1hr in 5% milk in TrisBuffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated in
primary antibody specific to mouse NPY Y1R, Y2R, and Y5R in 5% milk TTBS at a
concentration of 1:1000 at 4°C overnight. Membranes were washed in TTBS then
incubated in secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit
IgG, 1:2000) in 2% milk in TTBS for 1 hr. Membranes were washed three times and
bands were detected using an Immun-Star WesternC© chemiluminescent kit (Bio-Rad,
Hercules, CA, USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules,
CA, USA). Membranes were washed, stained for total protein using Amido black, and
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imaged using the ChemiDoc XRS. Densitometric band analysis was performed with
Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA).

2.2.6

Cell Proliferation Experiments
Twenty five hundred cells were seeded per well of 96-well plates and incubated

for 24 hrs in DMEM supplemented with 10% FBS. After 24 hrs media was replaced with
experimental medium (DMEM + 2% FBS) containing 10-11 to 10-6 M NPY (Tocris,
Minneapolis, MN, USA). The proliferative effect of NPY was tested using an MTS (3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
based assay (CellTiter 96® AQueous One Solution, Madison, WI, USA). Proliferation was
measured after 24 hr, 48 hr and 72 hr of NPY treatment. These experiments were
conducted in triplicate (per concentration) and repeated at least four times. These
experiments were repeated with Peptide YY (3-36) and Y5R specific agonist: [cPP17,NPY19-23,Ala31,Aib32,Gln34] - hPancreatic Polypeptide.
In order to elucidate the contribution of each respective receptor to NPYstimulated proliferation, receptor antagonist experiments were conducted. Twenty-four
hrs after cells were seeded, experimental media containing NPY (10-8 M, peak effective
dose) and one of three antagonists (BIBP3226, BIIE0246 or L-152) were added. For
each drug, increasing doses (10-9 M to 10-4 M) were added to wells and cell proliferation
was measured at 24, 48 and 72 hrs. Media was replaced every 24 hrs
(triplicate/concentration, n=4 per experiment). These experiments were repeated in the
absence of NPY to ensure antagonist treatment had no toxic or anti-proliferative effects.
Drugs were reconstituted in HBSS and all treatments were compared to control cells that
were incubated in experimental media containing an equal volume of HBSS as peptide,
agonist or antagonist treated cells.
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2.2.7

NPY-Stimulated ERK1/2 phosphorylation
NPY receptor activation has been shown to stimulate MAPK activity, leading to

increased ERK 1/2 phosphorylation (pERK) and cell proliferation. To confirm that our
NPY treatment stimulated MAPK activity in the 4T1 cell line, a time-point experiment was
conducted to examine the effect of NPY treatment (10-8 M) on pERK 1/2. 4T1 cells (5 x
104) were seeded in 60 mm diameter tissue culture dishes in culture media and left to
incubate for 24hrs. Cells were then growth-arrested for 24hrs with experimental DMEM
plus 0.1% BSA. Individual dishes were then treated with experimental media containing
NPY (10-8 M) for 2, 5, 15, 30 and 60 minutes (n=4/time point). After which, cells were
washed three times in ice cold HBSS, 100µl of lysis buffer was added to the dish and
cells were scraped. Lysates were centrifuged for 15 minutes at 14000 rpm at 4°C.
Supernatant was collected and stored at 4°C until protein concentration was determined
on the following day. Samples were then analyzed by Western blot for pERK and total
ERK expression using antibodies specific to each respective protein rabbit anti-mouse
phospho-p44/42 MAPK (Erk1/2) 1:1000 and rabbit anti-mouse p44/42 MAPK (Erk 1/2)
1:1000. Blots were repeated four times and densitometric analysis was conducted for
each blot. NPY stimulated phosphorylation of ERK 1/2 was quantified as the level of
pERK 1/2 normalized to total ERK 1/2.

2.2.8

Live/Dead® Viability Assay
To assess the effects of experimental drug treatments on cell viability we used a

two-color fluorescence cell viability assay (Live/Dead® Viability Kit, Molecular Probes,
Eugene, OR, USA). We repeated experimental conditions from proliferation experiments
(96-well format), cells were then treated with calcein acetoxymethyl ester (1µM) and
ethidium homodimer (2µM) according to manufacturer’s protocol. Fluorescence was
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measured on a microplate spectrofluorimeter (calcein acetoxymethyl ester excitation
filter: 485nm; emission: 530nm, ethidium homodimer excitation filter: 530nm; emission:
645nm). Data were expressed as a percent change of control.

2.2.9

Chemotaxis Assays
Cell chemotaxis was assessed using a modified Boyden chamber apparatus with

a 12-well plate and cell culture inserts with polyethylene terephthalate (PET) membranes
and 8µm pores (BD Biosciences). The upper surfaces of the insert membranes were
coated with 0.1% gelatin and left overnight. The following day, the gelatin surface was
rehydrated with serum-free media for 1 hr and 4T1 cells (1.5 × 105) were plated in the
upper chamber in serum-free media. To examine the chemotactic potential of NPY, cells
were exposed to a range of NPY-treated media (10-11-10-6 M) placed in the bottom
chamber. To examine receptor-specific effects of NPY on chemotaxis, cells were
incubated separately in Y1R, Y2R or Y5R antagonists for 30 minutes. After incubation,
cells were added to the upper chamber in wells containing a range of Y-receptor
antagonist treated serum free media (10-9-10-4 M), while NPY treated media (10-8 M,
previously determined peak effective dose) was added to the bottom chamber. All
treatments were carried out in triplicate and experiments were repeated at least three
times.

After 6 hrs of incubation, the gelatin and cells remaining on the top of the

membrane were removed using cotton swabs. Migrated cells (on the bottom of the
membrane) were fixed and stained with 0.5% Crystal violet in methanol. The
membranes were carefully removed, mounted on slides, and imaged using a light
microscope at 10x magnification (Zeiss Axioskop, Nikon DXM1200 camera). From the
images, the total number of migrated cells were manually counted and recorded. In all
cases, experimental conditions for slides were blinded during counting.
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2.2.10

Statistical Analyses

Statistical analysis was performed using GraphPad software, (Version 4.0a,
GraphPad Software Inc) and data are presented as mean ± SEM. Non-linear regression
analysis was performed on proliferation and chemotaxis experiments to test if the effects
of NPY were concentration-dependent and to determine the peak effective NPY dose to
be used in antagonist experiments. Statistical differences between treatments were
evaluated by one-way repeated measure ANOVA, followed by Tukey’s HSD test. The
level of statistical probability was set at P<0.05.

2.3 Results
2.3.1

NPY Receptor Expression in the 4T1 Cell Line
Quantitative real-time PCR revealed expression of mRNA for Y1R, Y2R and Y5R

in the 4T1 cell line (Figure 2.1 A). Additionally, receptor protein expression was
confirmed by Western blot analysis (Figure 2.1 B). Immunocytochemical staining
revealed positive Y1R, Y2R and Y5R expression in 4T1 cells (Figure 2.1 C).
Membranous and cytoplasmic staining was observed, with the Y5R exhibiting the most
prevalent expression. Y1R, Y2R and Y5R expression was also observed in histological
sections (Figure 2.1 D). Receptor expression was observed on tumor cell membranes
and was detected on blood vessel endothelium.
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Figure 2.1. Y1, Y2 and Y5 receptor expression. qPCR indicated NPY receptor mRNA
expression in the 4T1 cell line (A. CT values). Western blot analysis of cell and tumor
lysates provided evidence of Y1R, Y2R and Y5R expression in this model (brain as a
postive control) (B.). Immunohistochemical analysis (DAB and hematoxylin) of cells (C.)
and tumor sections (D.) confirmed NPY receptor expression. 4T1 cells exhibited positive
cytoplasmic and membranous staining of receptors; the Y5R subtype exhibiting the
greatest expression. In tumors, staining was observed on tumor cell membranes and
was also detected on blood vessel endothelium (C. scale bar = 10 µm; D. scale
sc
bar = 20
µm).
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2.3.2

Cell Proliferation Experiments
NPY treatment stimulated a concentration-dependent (r2=0.94) increase in

proliferation measured at 24 hrs (Figure 2.2 A), 48 hrs and 72 hrs (Appendix). When
compared to control cells, a proliferative effect of NPY was observed at 10-10 M and was
maximal at 10-8 M (P<0.05). Similarly, treatment with the Y5R specific agonist, [cPP17

,NPY19-23,Ala31,Aib32,Gln34]–hPP also stimulated a concentration-dependent increase in

proliferation (r2=0.97) after 24 hrs, at a concentration of 10-10 M, plateauing at a
concentration of 10-9 M (P<0.05, Figure 2.2 B).

2.3.3

Effect of NPY on Phosphorylation of ERK 1/2.
After 24 hrs of serum-free incubation low basal levels of pERK 1/2 were

observed (0 minute: Figure 2). NPY treatment significantly increased pERK 1/2 levels
after 2 minute and 5 minute incubations (Figure 2.2 A, P<0.05), and by 15 minutes pERK
1/2 levels returned to basal levels. Y5R agonist, [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPP
treatment caused an increase in pERK 1/2 levels after 5 minutes (P<0.05, Figure 2.2 B).
Increased pERK 1/2 activity could not be blocked by BIBP3226 and BIIE0246 at
concentrations from 10-8 to 10-4 M (Figure 2.3. A & B: 10-4 M and 10-5 M respectively).
NPY and Y5 agonist stimulated increased pERK 1/2 activity and was blocked by L152,804 (10-4 M) (P< 0.05, Figure 2.3 C & D).
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Figure 2.2. Effect of peptidergic treatment on proliferation and ERK1/2 phosphorylation of
4T1 cells. Proliferation (MTS assay) and ERK 1/2 phosphorylation (Western blot) were measured
-8

1-7

19-23,
23,

in cells treated with media containing NPY (10 M) (A.) and [cPP ,NPY

31

32

34

Ala ,Aib ,Gln ]–

-9

hPP (10 M) (B.). A concentration
concentration-dependent
dependent increase in proliferation was observed after 24 hrs
2

of peptide treatment (r =0.94 and 0.97 respectively). Peptide treatment significantly increased
proliferation compared to cells in experimental medium (Ctrl; DMEM + 2% FBS, n=4, P<0.05).
Western blot analysis was used to examine ERK 1/2 phosphorylation in cells treated with NPY
1-7

19-23

(A.) and [cPP ,NPY

31

32

34

,Ala ,Aib ,Gln ]–hPP
hPP (B.) for 2 minutes, 5 minutes, 15 minutes, 30

minutes and 1 hr. Peptide treatment stimulated an increase in pERK 1/2 at 2 minutes (NPY) and
1-7

19-23

5 minutes (NPY and [cPP ,NPY

31

32

34

,Ala ,Aib ,Gln ]–hPP)
hPP) after which pERK 1/2 levels

returned to non-treated
treated levels (0 minutes). Densitometric data are presented as pERK 1/2
normalized to total ERK 1/2. Data are presented as mean ± SEM (n=4, * represents differences
from Ctrl. P<0.05, one-way
way A
ANOVA).
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Figure 2.3. Effect of NPY receptor activation and blockade (Y1R, Y2R and Y5R) on
cell proliferation and ERK 1/2 phosphorylation. Cells were treated with NPY (10-8 M)
and one of three antagonists (A. Y1R: BIBP3226; B. Y2R: BIIE0246; C. Y5R: L-152,804;
10-8-10-4 M). NPY-stimulated proliferation was not blocked by Y1R antagonism or Y2
antagonism (Y1R: 10-4 M Y2R: 10-5 M). Y5R antagonism (10-4 M) abolished the
proliferative effects of NPY (*P<0.05). Y5R agonist treatment (D., [cPP1-7,NPY1923

,Ala31,Aib32,Gln34]–hPP 10-9 M) caused an increase in proliferation which was blocked

by L-152,804. ERK 1/2 phosphorylation increased when cells were treated with NPY and
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP; this effect was blocked by L-152,804 treatment.
Panels depict peak antagonist concentrations used, all experiments were repeated four
times (n=4), data are presented as mean ± SEM (* Represent differences from Ctrl.
P<0.05, one-way repeated measures ANOVA).
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2.3.4

Effect of NPY receptor blockade (Y1, Y2 and Y5) on cell
proliferation.
The independent contributions of Y1R, Y2R and Y5R activation on proliferation

were tested by receptor-specific antagonist supplementation. Cells were incubated with
media containing NPY (10-8 M, peak proliferative concentration) and BIBP3226,
BIIE0246 or L-152,804 (10-8 to 10-4 M). At all time points, NPY treatment led to increased
proliferation compared to vehicle containing media (Control) (P<0.05, Figure 2.3). Of the
three antagonists tested, only the Y5R antagonist (L-152,804) inhibited the proliferative
effect of NPY (P<0.05, Figure 2.3 C). Compared to control, there was no change in NPY
stimulated proliferation in cells exposed to Y1R antagonism (BIBP3226) (Figure 2.3 A:
10-4 M) or Y2R antagonism (BIIE0246) (Figure 2.3 B: 10-5 M). Y5R agonist treatment (109

M) also caused an increase in proliferation which was blocked by L-152,804 (Figure 2.3

D: 10-4 M). Control experiments were conducted with each antagonist in the absence of
NPY, and we observed BIIE0246 to be toxic at 10-4 M, while no toxic or proliferative
effects were observed from L-152,804 or BIBP3226 treatment at concentrations (10-8 to
10-4 M) used in blockade experiments (Figure 2.4).

2.3.5

Cell Viability
NPY treatment (10-8 M) led to an increase in the percent of live cells compared to

control and had no effect on cell death (P<0.05, Figure 2.4). Treatment with [cPP17

,NPY19-23,Ala31,Aib32,Gln34]–hPP (10-9 M) led to a similar increase in the percent of live

cells. Compared to control cells, independent treatment with the receptor antagonists
BIBP3226 (10-4 M), BIIE0246 (10-5 M) or L-152,804 (10-4 M) had no effect on cell viability
or cell death.
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Figure 2.4 Effect of peptide and antagonist treatments on cell viability. The effect of
experimental drug treatments (from proliferation experiments) on cell viability was
assessed with a Live/Dead® viability assay. Cells were treated for 24 hrs with NPY (108

M) , [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP (Y5R agonist; 10-9 M), BIBP3226 (10-4 M),

BIIE0246 (10-5 M), or L-152,804
152,804 (10-4 M). Calcein (Live, emission: 530 nm) and ethidium
(Dead, emission: 645 nm) fluorescence was measured and compared to control cells
(DMEM + 2% FBS). NPY and Y5R agonist treatment led to an increase in the percent of
live cells and there was no effect of these drug treatments on cell death. Data are
expressed as a percent change of control ((mean ± SEM; n=6; * represents
epresents differences
from Ctrl. P<0.05, one-way
way ANOVA).
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2.3.6

NPY- Stimulated Chemotaxis
NPY induced a concentration-dependent increase in chemotaxis with a peak

concentration of 10-8 M (Figure 2.5 A). At NPY concentrations of 10-9 to 10-6 M,
chemotaxis was significantly augmented compared to untreated cells (Ctrl). Similarly,
PYY3-36 (Y2R/Y5R agonist) and Y5R agonist treatment stimulated a concentrationdependent increase in chemotaxis (Figure 2.5 B & C). Treatment of cells with Y1R
antagonist (BIBP3226) had no effect on NPY-stimulated chemotaxis (Figure 2.6 A),
whereas Y2R blockade (BIIE0246) attenuated NPY-mediated increases in cell
chemotaxis at 10-6 M (P<0.05, Figure 2.6 B). In addition, NPY-mediated increase in cell
chemotaxis was attenuated when cells were treated with Y5R antagonist (L-152,804) at
all concentrations tested (10-8-10-4 M) (P<0.05, Figure 2.6 C).
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Figure 2.5 Peptidergic stimulated chemotaxis of 4T1 cells. Cell chemotaxis was
assessed using a modified Boyden chamber. Cells were seeded (2 × 104 cells) in serumfree media in the top chamber and were exposed to A. NPY, B. PYY3-36 (Y2R/Y5R
agonist), and C. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP (Y5R agonist) (10-11-10-6 M) in
DMEM in the lower chamber. After 24 hrs migrated cells were fixed, stained with DAPI
and imaged. Cells were counted by Matlab® based software. Peptide treatment elicited a
concentration-dependent increase in chemotaxis compared to control cells. Data are
presented as mean ± SEM, (n=4, * represent differences from Ctrl; P<0.05, one-way
ANOVA).

45

46

Figure 2.6 Effect of NPY receptor activation and blockade (Y1R, Y2R and Y5R) on
chemotaxis. NPY receptor antagonists A. Y1R: BIBP3226; B. Y2R: BIIE0246; and
C.Y5R: L-152,804) were added to the upper chamber (10-8-10-4 M) and NPY treated
media (10-8 M) was added to the bottom chamber. Treatment of cells with BIBP3226 had
no effect on NPY-stimulated chemotaxis, while BIIE0246 and L-152,804 inhibited the
chemotactic effects of NPY. The data are presented as the mean ± SEM,
represent differences from Ctrl. P<0.05, one-way ANOVA).

(n=4, *
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2.4 Discussion
A neuroendocrine influence on breast cancer progression has been a postulate
of recent interest. In the current, study we have presented data supporting this postulate
in the 4T1 breast cancer model. We report for the first time the expression of the Y1R,
Y2R and Y5R in the 4T1 cell line, in culture and in primary tumors. Additionally, we
observed NPY-stimulated proliferation through Y5R activation, and signaling via ERK 1/2
phosphorylation. Finally, we have shown that NPY is a potent chemoattractant acting
through Y2R and Y5R activation.
The expression of NPY receptors (Y1R, Y2R and Y5R) in the 4T1 cell line
observed in the current study is congruent with others reporting the presence of NPY
receptors in several different carcinomas including prostate (Magni & Motta, 2001),
ovarian (Korner, Waser, & Reubi, 2004), and breast (Reubi, et al., 2001; Sheriff, et al.,
2010). Reubi et al. (Reubi, et al., 2001) reported expression of Y1R in 85% of the breast
carcinomas sampled, while 24% were positive for Y2R. In all cases, Y2R positive tumors
also expressed Y1R. Furthermore, in the same study, normal breast tissue expressed
Y2R only. Y5R expression in breast cancer tumors was not investigated in the
aforementioned study; however, a recent publication from Sheriff et al. (Sheriff, et al.,
2010) reported Y5R transcript and protein expression in several human breast cancer
cell lines. In the 4T1 cell line we observed Y1R, Y2R, and Y5R expression and our Y1R
and Y5R mRNA levels paralleled those recently reported by Sheriff et al. (Sheriff, et al.,
2010). Based on our immunohistochemical observations Y5R expression predominates
over Y1R and Y2R expression in 4T1 cells and tumors.
NPY has been shown to stimulate proliferation in prostate cancer (Ruscica, et al.,
2006), neuroblastomas (Kitlinska, 2007b) and breast carcinomas (Amlal, et al., 2006;

48

Sheriff, et al., 2010). In the current study we observed a concentration-dependent
increase in proliferation with NPY treatment, with proliferation occurring in physiological
concentrations of NPY (10-10-10-8 M) (Drell, et al., 2003). Additionally, Y5R agonist
treatment induced a concentration-dependent increase in proliferation. Y1R (BIBP3226)
or Y2R (BIIE0246) antagonism did not attenuate NPY-stimulated proliferation; however,
Y5R blockade (using L-152,804) produced concentration-dependent attenuation of
NPY’s effects. In support of these data, Y5R blockade inhibited the proliferative effects
of the specific Y5R agonist treatment. This set of experiments illustrates the predominant
role that the Y5R plays in NPY mediated proliferation in this cell line. These findings
follow those reported in neuroblastomas and human breast cancer cells (Kitlinska,
2007a; Sheriff, et al., 2010). Y5R activation has been shown to stimulate MAPK activity,
leading to increased ERK 1/2 phosphorylation and cell proliferation (Pellieux, et al.,
2000; Sheriff, et al., 2010; Zukowska-Grojec, Karwatowska-Prokopczuk, Fisher, & Ji,
1998). Sheriff et al. (Sheriff, et al., 2010), reported that Y5R activation led to an increase
in pERK 1/2 in BT-549 cells, an effect that was inhibited by Y5R blockade. We observed
a similar increase of pERK 1/2 levels after 2 minutes and 5 minutes of NPY treatment
and Y5R agonist treatment, a response that could only be blocked by Y5R antagonism,
further supporting that Y5R activation promotes NPY-stimulated proliferation.
Neuropeptides have been implicated to be involved in the development of
metastasis (Drell, et al., 2003). The migratory propensity of MDA MB-231 cells has been
shown to increase when treated with NPY, a response that was mediated by Y5R
activation (Sheriff, et al., 2010). In our current study, we observed that NPY acts as a
concentration-dependent chemoattractant and it appears that NPY-mediated chemotaxis
occurs through Y2R and Y5R activation. Accordingly, chemotaxis increased when cells
were exposed to PYY3-36 (Y2R/Y5R agonist) and [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP
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(Y5R agonist). Similar NPY-stimulated migration has been reported in endothelial cells
as a result of Y2R and Y5R activation (Movafagh, et al., 2006).
The immune system influences microenvironmental interactions between tumor
cells and the host–tissue; such interactions mediate primary tumor development and
play an important role in the metastatic cascade. Thus, in many human cell xenograft
models in immunocompromised mice, metastatic development can often be variable and
sometimes unpredictable (Bibby, 2004; Eccles, Box, Court, Sandle, & Dean, 1994). The
4T1 murine mammary carcinoma represents a syngenic model that effectively
metastasizes and exhibits similar metastatic characteristics to those clinically observed
(Lin, et al., 1998; Pulaski & Ostrand-Rosenberg, 1998, 2001). Positive Y2R expression
in this model contrasts the recent report that many human breast cancer cell lines lack
this receptor (Sheriff, et al., 2010). Based on the work of others (Reubi, et al., 2001), we
acknowledge that the Y2R effects observed in the current study may be relevant to a
small subset of human breast carcinomas. However, our current findings highlight the
complexity and heterogeneity of the NPY system in breast cancer. As it stands, this
model enables the investigation of all three receptors (Y1R, Y2R, and Y5R) and their
influence on breast cancer tumor formation.
Overall, we report the presence of Y1R, Y2R and Y5R receptors in the 4T1
murine breast cancer cell line for the first time. More importantly, we have shown that
NPY (at physiological levels) is a potent proliferative and chemotactic agent in the 4T1
cell line, acting through the Y5R and Y2R/Y5R respectively. Our findings support the
accumulating evidence demonstrating the pathological contribution of NPY and its
respective receptors in the development and progression of breast cancer. Given our
current findings and previously reported interactions between stress, the sympathetic
nervous system, the immune system and tumor cells, we propose the 4T1 cell line as a
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syngenic model for future in vivo investigations addressing the integrated functional
effects of NPY on breast cancer growth/progression and metastasis.
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Chapter 3

3

Neuropeptide Y promotes angiogenesis by increasing
expression and secretion of VEGF from breast cancer
cells

Content from this chapter will be submitted as a manuscript to Microvascular Research.

3.1 Introduction
The involvement of stress-related factors to the initiation and progression of breast
cancer has been a question of growing interest, with recent attention given to
neurotransmitters of the sympathetic nervous system (norepinephrine: NE and
neuropeptide Y: NPY). Through ß-adrenergic activation, NE has been shown to increase
tumor growth, metastasis, and stimulate angiogenesis (Raju, Haug, Ibrahim, &
Heyeraas, 2007; Shakhar & Ben-Eliyahu, 1998; Sloan, et al., 2010; Thaker, et al., 2006;
Yang, et al., 2006). Congruently, NPY has been reported to increase proliferation and
migration of breast cancer cells (Medeiros, et al., 2012; Sheriff, et al., 2010), and
promote vacularization of neuroendrocrine tumors (Kitlinska, 2007; Kitlinska, et al.,
2005).
Neuropeptide Y, a 36-amino acid peptide released by sympathetic nerves, is a potent
trophic factor that can promote angiogenesis (Movafagh, Hobson, Spiegel, Kleinman, &
Zukowska, 2006; Zukowska-Grojec, Karwatowska-Prokopczuk, Rose, et al., 1998). In
mammals, angiogenesis occurs in exercised skeletal muscle (Burton & Barclay, 1986;
Mai, Edgerton, & Barnard, 1970), ischemic tissue (Semashko, Song, Silverman, &
Weinberg, 1985), the uterus during pregnancy (Lindenbaum, Langer, & Beach, 1991;
Tamura & Greenwald, 1987), and during wound healing (Folkman, 1974; Knighton,
Silver, & Hunt, 1981). In pathologies such as cancer, tumor development is dependent
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on heightened angiogenic activity in order to supply the growing tumor with oxygen and
nutrients. Angiogenesis is a multi-faceted process that involves many cytokine pathways
that interact with the endothelium and smooth muscle. Under physiological
concentrations, NPY has been shown to stimulate adhesion, migration, proliferation and
capillary tube formation in human endothelial cells in vitro (Zukowska-Grojec,
Karwatowska-Prokopczuk, Rose, et al., 1998). These responses were found to occur
bimodially via Y1R, Y2R or Y5R activation (Movafagh, et al., 2006). The role of the Y2R
is supported in vivo, where,Y2R knockdown mice exhibit compromised wound healing,
associated with blunted angiogenesis (Ekstrand, et al., 2003; Lee, Grant, Movafagh, &
Zukowska, 2003). Along the same line, Y2R knockdown mice display attenuated,
hypoxia-induced retinal angiogenesis (Koulu, et al., 2004). Finally, exongenous NPY has
been reported to increase tumor vascularization in neuroblastoma and Ewing’s sarcoma
xenografts (Kitlinska, et al., 2005).
Sympathetic neurotransmitters can function in a paracrine manner, stimulating the
release of cytokines such as interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis
factor α (TNFα), and vascular endothelial growth factor (VEGF) (Madden, Szpunar, &
Brown, 2011; Tan, et al., 2007; Yang, et al., 2009). Activation of ß-adrenergic receptors
on breast cancer cells and/or host stromal cells has been shown to cause the release of
VEGF (Madden, et al., 2011). These responses occur via a cyclic adenosine
monophosphate (cAMP) - protein kinase A (PKA) pathway, where ß-adrenergic
receptors activation leads to increased cAMP, causing an activation of PKA, signaling for
downstream changes in gene expression. NPY receptors belong to the family of Gprotein coupled receptors, which when activated cause inhibition of adenylate cyclase,
leading to an decrease in cAMP (Zhu, Li, Toews, & Hexum, 1992).
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As described above, previous studies demonstrate NPY’s potential to promote
angiogenesis through its actions on vascular smooth muscle and endothelial cells
(Movafagh, et al., 2006; Zukowska, Grant, & Lee, 2003) However, to our knowledge,
whether activation of NPY receptors on breast cancer cells promotes VEGF secretion
(i.e., paracrine) remains to be tested.
The 4T1 breast cancer cell line is a syngeneic murine model of breast cancer, used by
our group and others, that displays growth, metastatic and angiogenic patterns that
parallel those of aggressive human cancers (Lin, et al., 1998; Prewett, et al., 1999).
Recently, we reported the expression of NPY receptors (Y1R, Y2R, and Y5R) in 4T1
cells, and found Y5R activation stimulated an increase in proliferation and Y2R and Y5R
stimulated migration (Medeiros, et al., 2012). Using this model (in parallel with the MDAMB-231 human cell line), we tested the hypothesis that NPY promotes angiogenesis by
augmenting expression and secretion of the pro-angiogenic factor VEGF within and from
breast cancer cells.
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3.2 Methods
3.2.1

Reagents and Drugs

Fetal bovine serum (FBS), culture media, DPBS and trypsin were purchased from
Invitrogen (Invitrogen Canada Inc., Burlington, ON). Cell lysis buffer (M-PER Mammalian
Protein Extraction Reagent) and protease inhibitors (Halt Protease Inhibitor Cocktail)
were purchased from Pierce (Rockford, IL). For Western blot analysis, we used rabbit
polyclonal antibodies, reactive with mouse and human VEGF (Cat no. ab46154, Abcam,
Cambridge, MA, USA) and Beta Actin (Cat no. ab8227, Abcam, Cambridge, MA, USA).
For secondary incubation we used antibody conjugated to horseradish peroxidase (goat
anti-rabbit IgG, Cat no. 170-6515, Biorad, Hercules, CA, USA). NPY (non-specific YR
agonist), [Leu31,Pro34]-Neuropeptide Y (Y1R agonist), Peptide YY (3-36) (Y2R agonist),
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPancreatic

Polypeptide

(Y5R

agonist),

Scrambled NPY peptide (Negative control), BIBP3226 (Y1R antagonist), BIIE0246 (Y2R
antagonist), and L-152,802 (L-152; Y5R antagonist), were from Tocris (Missouri, USA)

3.2.2

Cell Culture
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan USA),

were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM)
supplemented with 10% sterile FBS. MDA-MB-231 cells were from the ATCC, cultivated
with RPMI medium with 10% sterile FBS. Human umbilical endothelial vein cells
(HUVEC) we purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON) and
cultivated with Medium 131 (Invitrogen Canada Inc., Cat no. M-131-500, Burlington, ON)
supplemented with Microvascular Growth Supplement (Invitrogen Canada Inc., catalog
#S-005-25, Burlington, ON). All cells were incubated at 37ºC and 5% carbon dioxide. At
approximately 80% confluency, cells were washed with DPBS and passaged using
0.25% trypsin-EDTA treatment for dissociation.
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3.2.3

Western blot Analysis - VEGF Expression
Western blot analysis was used to test the effect of Y-receptor activation on

VEGF expression in 4T1 and MDA-MB-231 cells. Cells were seeded in 60mm culture
dishes at a density of 5x105 4T1 cells, and 1x106 MDA-MB-231 cells. After a 24hr
incubation period cells were serum starved for 24hr, then treated with NPY (10-10-10-7 M),
Y-receptor agonist (10-10-10-7 M), or NPY-scrambled peptide containing medium
(negative control). Three receptor agonist treatments (Y1R, Y2R and Y5R) were tested
with the 4T1 cells, whereas with MDA-MB-231 cells, given they only express the Y5R,
experiments were only conducted with NPY and Y5R agonist treatments. Additionally,
with the 4T1 cells blockade experiments were conducted BIBP3226 (Y1R antagonist),
BIIE0246 (Y2R antagonist), and L-152,802 (L-152; Y5R antagonist) in order to support
agonist experiments. After 24hr culture medium was removed, cells were washed three
times in ice cold HBSS and then lysed in 500 µl lysis buffer containing protease inhibitor
(104 mM AEBSF, 80 µM aprotinin, 2.1 mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin
A, 1.4 mM E-64). Cells were scraped and then lysed by sonication. Cell lysates were
centrifuged for 15 minutes at 14,000 rpm at 4°C. Supernatant was collected and stored
at -80°C until protein concentration was determined.
Protein concentration was determined by Bradford assay (Bradford, 1976). Twenty
micrograms of protein from each sample was loaded on a 4% to 12% gradient gel and
separated by SDS-PAGE. Proteins were transferred at a constant voltage to
polyvinylidene fluoride membranes. Membranes were blocked overnight in 5% milk in
Tris-Buffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated
in primary antibody specific to VEGF in 5% milk TTBS at a concentration of 1:2000 at
room temperature for 1hr. Membranes were washed in TTBS then incubated in
secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit IgG,
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1:20000) in 2% milk in TTBS for 1hr. Membranes were washed three times and bands
were detected using an Immun-Star WesternC© chemiluminescent kit (Bio-Rad,
Hercules, CA, USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules,
CA, USA). To ensure equal loading, membranes were stripped, washed and then
probed for beta actin (1:5000 primary antibody concentration, 1:20000 secondary
concentration). Densitometric band analysis was performed with Quantity One 1-D
Analysis Software (Bio-Rad, Hercules, CA, USA).

3.2.4

VEGF Enzyme-linked immunosorbent assay (ELISA)
VEGF secretion from 4T1 cells was measured in conditioned medium using

ELISA (R&D Systems, Inc., Cat no. MMV00, Minneapolis, MN 55413, USA). Assays
were conducted following manufacture’s protocol. Briefly, reagents were brought to room
temperature. Standards and samples (50 µl) were pipetted in duplicate. After a 2hr
incubation the plate was washed five times, and then 100 µL of Mouse VEGF Conjugate
was added to each well. After 2hr incubation the plate was washed again, then 100 µl of
TMB peroxidase substrate solution was added to all wells. The reaction was stopped
after 30 minutes by adding the stop solution. The optical absorbance of each well was
read at 450 nm (Bio-Rad Ultramark Microplate Imaging System, Bio-Rad, Hercules, CA,
USA). The assay has a minimum detectable concentration of less than 3.0 pg/mL.
(manufacturer's data).

3.2.5

Conditioned Medium
In order test if NPY stimulation of cancer cells would promote angiogenesis in

vitro, we conducted endothelial tube formation assays with conditioned media from 4T1
and MDA-MB-231 cells. Following a similar approach described for VEGF western blot
experiments, cancer cells were seeded in 60mm culture dishes, and after a 24hr
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incubation period, cells were serum starved for 24hr, then treated with NPY (10-10-10-7 M)
or one of three Y-receptor agonists (10-10-10-7 M). NPY-scrambled peptide containing
medium was used as a negative control. VEGF treated media was used as a positive
control.

3.2.6

Endothelial Tube Formation Assays
Tube formation assays were conducted in 24-well tissue culture plates. Wells

were coated with diluted Growth factor–reduced Matrigel (280 µL; 1:1 with DMEM, BD
Biosciences, San Jose), then left to polymerize for 1hr at 37°C. Low passaged (< 5)
Human umbilical vein endothelial cells (HUVEC) were cultured for no more then two
weeks prior to tube formation assays. HUVEC were suspended in conditioned or nonconditioned media and were then plated at a density of 7.5 x104 per well. Plates were
then incubated for 6hrs at 37°C and 5% CO2. Wells were imaged (5 random
images/well) using a light microscope at 5x magnification (Zeiss Axioskop, Nikon
DXM1200 camera). The total number of branch points (BP) and complete endothelial
networks (EN) were counted in each image and averaged per well.

Each

treatment/condition was assayed in duplicate, and experiments were repeated 3-4 times.

3.2.7

Statistical Analyses
Statistical analysis was performed using GraphPad software. (Version 4.0a,

GraphPad Software Inc) Data are presented as mean ± SEM. Statistical differences
between treatments were evaluated by one-way ANOVA, followed by Tukey’s HSD test.
The level of statistical probability was set at P<0.05.
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3.3 Results
3.3.1

VEGF Expression
Western blot analysis was used to examine the effect of NPY receptor activation

on VEGF expression in both the 4T1 and MDA-MB-231 cells. Twenty-four hours of NPY
treatment (10-9M) caused a 52% ±14 increase in VEGF expression in the 4T1 cells
compared to non-treated controls (Figure 3.1 A.). Similarly VEGF expression was
significantly greater (61%±10) in NPY treated MDA-MB-231cells compared to nontreated cells, at a concentration of 10-8 M (Figure 3.1 B.). Scrambled NPY peptide
treatment had no effect on VEGF expression (p >0.05).
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Figure 3.1 NPY stimulates an increase in VEGF expression. An increase in VEGF
expression was observed in 4T1 (A.) and MDA
MDA-MB-231
231 (B.) cells treated with NPY for
24hrs. In the 4T1 cells a 52%±14 increase (p <0.05) in VEGF expression compared to
non-treated
treated control cells was observed at 10-9 M NPY. A 61%±10 (p <0.05) increase in
VEGF was observed at 10-8 M NPY in the MDA-MB-231
231 cells (p <0.05). (mean ± SE,
way ANOVA)
n=4, * p<0.05, one-way
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3.3.2

NPY Treated Conditioned Media
Endothelial tube formation assays were conducted using conditioned media from

4T1 and MDA-MB-231 cells. NPY treated conditioned media, at concentrations of 1010 10-7 from 4T1 cells caused a significant increase in BP and EN (Figure 3.2 A.). Similarly,
NPY treated CM from MDA-MB-231 elicited a 7-fold increase in BP and 9-fold increase
in EN at 10-10 M, EN continued to increase at higher concentrations, up to 22-fold at 10-7
M NPY (Figure 3.2 B.). Scrambled NPY treated conditioned media had no effect on BP
or EN compared to control. The non-conditioned NPY media caused a modest increase
in BP and EN, which was statistically less than the pro-angiongenic effects caused by
NPY treated conditioned media.
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Figure 3.2 NPY treated conditioned media promotes in vitro angiogenesis. NPY
CM from 4T1 (A.) and MDA
MDA-MB-231
231 cells stimulated an increase in branch points and
complete endothelial networks. CM from 4T1 cells elicited a 2
2-fold
fold increase in BP and 4fold increase in EN at 10-8 M NPY. MDA-MB-231 CM stimulated a 7-fold
fold increase in BP
and 9-fold
fold increase in EN at 10-10 M, EN continued to increase at higher concentrations
(~22-fold at 10-7 M NPY). (mean ± SEM, n=4,

* p<0.05, one-way
one
ANOVA)

Representative
presentative images depict response during control, scrambled NPY (10-9M), NPY
(10-8M) and VEGF treatments.
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3.3.3

Y-Receptor agonist treated conditioned media
In order to elucidate the contribution of each of the NPY receptors expressed in

the 4T1 cell line (Y1R, Y2R and Y5R) to the pro-angiogenic response observed with
NPY treated conditioned media, Y-receptor agonist experiments were conducted.
Conditioned media from Y1R-agonist treated cells (Figure 3.3 A.) and Y2R-agonist
treated cells (Figure 3.3 B.) had no effect on increasing in vitro angiogenesis. Whereas,
conditioned media from 4T1 cells treated with Y5R agonist elicited a 3-fold increase in
BP and an 8-fold increase in EN at a concentration of 10-9 M (p <0.05).
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Figure 3.3 Effects of Y
Y-receptor
receptor agonist treated conditioned media on in vitro
angiogenesis. 4T1 cells were treated with Y1R agonist; [Leu31,Pro34]-NPY
[Leu31,Pro34]
(A.), Y2R
agonist; Peptide YY (3-36)
36) (B.) or Y5R agonist; [cPP1-7,NPY19-23,Ala31,A
23,Ala31,Aib32,Gln34]–
hPP (C.), conditioned media from these experiments was tested on HUVEC. Y1R
agonist, and Y2R agonist treatment had no effect on stimulating in vitro angiogenesis.
Y5R agonist treated conditioned media caused an increase in BP and EN. ). (mean ±
SEM, n=4, * p<0.05, one
one-way ANOVA)
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3.3.4

VEGF Release
VEGF release was quantified in conditioned media from agonist experiments

using ELISA. VEGF was elevated 2.5-fold in NPY treated conditioned media compared
to non-treated controls. Y1R agonist treatment and Y2R agonist treatments had no effect
on VEGF release, while Y5R agonist treatment cause a 2.5-fold increase at 10-9M.
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Figure 3.4 Effect of Y-receptor stimulation on VEGF release. 4T1 cells were treated
with NPY, Y1R agonist; [Leu31,Pro34]-NPY, Y2R agonist; Peptide YY (3-36) or Y5R
agonist; [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP for 24hr. VEGF release was
measured in conditioned media and compared to non-treated control conditioned media.
NPY and Y5R agonist treatment induced a greater than two-fold increase in VEGF
release. (Each experiment in duplicate)
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3.3.5

Y-Receptor Stimulated VEGF Expression.
VEGF expression was quantified after Y-receptor agonist treatments. Western

blot analysis revealed no effect of Y1R agonist (Figure 3.5 A.), or Y2R agonist (Figure
3.5 B.) treatment on VEGF expression in 4T1 cells. Y5R agonist treatment cause a 2.5fold increase in VEGF expression in 4T1 cells compared to non-treated controls (Figure
3.5 C.), and 1.6-fold increase in MDA-MB-231 cells (Figure 3.5 D.) (p<0.05). Additionally,
a control experiment was conducted where Y-receptor antagonists were used in
combination with NPY treatment. NPY treatment (10-9M) caused a 51% increase in
VEGF expression, Y1R antagonism using BIBP3226 (10-5M) (Figure 3.6 A.) and Y2R
antagonism with BIIE0246 (10-5M) (Figure 3.6 B.) had no effect in blocking the NPY
stimulated increase in VEGF expression. Whereas the effects of NPY on VEGF
expression were abolished when cells were treated with L152,802 (10-5M) (Figure 3.6
C.)
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Figure 3.5 Effect of Y
Y-receptor
receptor agonist treatment on VEGF expression. VEGF
expression was probed for after 24hrs of Y
Y-receptor
receptor agonist treatment. Y1R agonist (A.)
and Y2R agonist (B.) treatments had no effect on VEGF expression. Y5R agonist
ag
treatment caused in increase in VEGF expression in 4T1 cells (C.) and MDA-MB-231
MDA
cells (D.) (mean ± SEM, n=3
n=3-4, * p<0.05, one-way ANOVA).
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Figure 3.6 The effect of Y-receptor blockade on NPY-stimulated VEGF expression.
NPY (10-9M) stimulated a 51% increase VEGF expression in 4T1 cells compared to nontreated controls. After preliminary experiments, Y1R antagonism using BIBP3226 (105

M) (A.) and Y2R antagonism with BIIE0246 (10-5M) (B.) had no effect in blocking the

NPY stimulated increase in VEGF expression. Y5R antagonism with L152,802 (10-5M)
(C.) blocked the effects of NPY on VEGF expression. (mean ± SEM, n=2)
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3.4 Discussion
In the current study we sought to elucidate the angiogenic properties of NPY in a
breast cancer model.

Earlier studies, have demonstrated NPY can promote

angiogenesis via direct stimulation of smooth muscle cells and the endothelium.
However, in the current study we illustrate a paracrine mechanism in which NPY may be
involved in the angiongenic cascade in breast cancer, as NPY receptor activation on
breast cancer cells increased the expression and secretion of the pro-angiogeneic factor
VEGF.
VEGF, a member of the family of platelet-derived growth factors, is one of the
primary

pro-angiogenic

factors

that

regulates

angiogenesis

in

the

tumor

microenvironment. VEGF is subdivided into seven members, of which the ~45 kDa
VEGF-A peptide, has been described as the major mediator of angiogenesis (Ferrara,
2002), and its presence has been negatively correlated with the survival of certain
cancers (Larcher, Murillas, Bolontrade, Conti, & Jorcano, 1998). It is well established
that many cell types express VEGF, including stromal, endothelial and cancer cells. As
well, in vitro studies have demonstrated that NE increases VEGF expression in MDAMB-231BR cells, through beta-adrenergic activation (Madden, et al., 2011; Tan, et al.,
2007; Yang, et al., 2009). However, we are the first to report NPY as a regulator of
VEGF expression in 4T1 and MDA-MB-231 cancer cell lines.
As measured from NPY-CM, we also observed that physiological concentrations
of NPY evoked increased VEGF secretion from the 4T1 cell line. NPY has been shown
to stimulate an increase in the secretion of VEGF from human dental pulp fibroblasts as
well as other pro-angiogenic factors (El Karim, Linden, Irwin, & Lundy, 2009). Moreover,
paracrine effects of NPY on VEGF release have been reported in ischemic skeletal
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muscle (Lee, Michalkiewicz, et al., 2003). In breast cancer, NPY has been postulated to
exert pro-angiogenic effects by directly acting on tumor vessels and/or endothelium, by
promoting proliferation of smooth muscle cells and stimulating adhesion, migration,
proliferation and capillary tube formation in endothelial cells (Tilan & Kitlinska, 2010;
Zukowska-Grojec, Karwatowska-Prokopczuk, Rose, et al., 1998). Although these past
studies reported that NPY exhibits direct angiogenic effects on vascular cells, we are the
first to demonstrate that in breast cancer, NPY can promotes a pro-angiogenic
microenvironment by working in concert with cancer cells as a paracrine system.
Functionally, VEGF stimulates proliferation, sprouting, migration and capillary formation
of endothelial cells (Otrock, Makarem, & Shamseddine, 2007; Papetti & Herman, 2002).
In the current study, the VEGF concentration measured in CM from NPY treated cancer
cells was more than 2-fold greater that non-treated controls. Our VEGF data is in
congruence with data from our functional angiogenic assays, where we demonstrated
that conditioned media from NPY treated cancer cells elicited a robust angiogenic
response. This was observed as 2-fold increase in BP and 4-fold increase in EN from
4T1 CM and MDA-MB-231 CM stimulated a 7-fold increase in BP and 9-fold increase in
EN.
Activation of ß-adrenergic receptors have been shown to increase VEGF
expression on breast cancer cells (Madden, et al., 2011). In the current study, we sought
to determine if activation of NPY receptors could elicit a similar response. Studies have
shown the Y2R and Y5R to be involved in NPY’s proangiogenic responses in skeletal
and smooth muscle, endothelial cells, retina and neuroblastomas, (Ekstrand, et al.,
2003; Kitlinska, et al., 2005; Koulu, et al., 2004; Lee, Grant, et al., 2003; ZukowskaGrojec, Karwatowska-Prokopczuk, Fisher, & Ji, 1998). We observed that Y5R activation
stimulated an increase in VEGF expression, while Y1R and Y2R activation had no effect
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on VEGF expression in the 4T1 cell line. Moreover, these findings were repeated in
human MDA-MB-231 cells, which only express Y5R. Accordingly, NPY-stimulated
increases in VEGF expression were blocked by Y5R antagonism using L152,802. The
Y5R has received recent attention for its role as a mediator of proliferation and migration
in breast cancer (Medeiros, et al., 2012; Sheriff, et al., 2010), however our current
findings provide additional pathological implications of the Y5R in the context of breast
cancer.
In summary, we have determined that NPY functions as a paracrine system with
cancer cells to promote angiogenesis. NPY Y5R activation of cancer cells led to
increased expression and release of the VEGF from 4T1 and MDA-MB-231 cells.
Although the objective of the current study was to examine the effects of NPY on VEGF
expression and release from breast cancer cells, certainly future studies should consider
other proangiogeneic factors such as IL-6, FGF, Ang1, Ang2, PDGF and MMP.
Furthermore, future experiments blocking the VEGF pathway are required to confirm the
responses observed in the current study. Additionally, the direct contribution of NPY to
endothelial vessel formation must be accounted for in future control experiments.
In conclusion, the results from the current study further support the 4T1 cell line
as a syngeneic model for future in vivo investigations addressing the integrated
functional effects of NPY on breast cancer angiogenesis. Moreover, NPY receptor
expression and function should be considered in future development of therapeutics to
inhibit tumor growth and angiogenesis.
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Chapter 4

4

The 4T1 breast cancer model, a syngeneic model of
breast cancer for the functional study of the
sympathetic neuropeptide Y system

4.1 Introduction
Neuropeptide Y (NPY), the most abundantly expressed peptide of the pancreatic
polypeptide family in mammalian systems, exherts pleiotropic actions throughout the
body. The 36-amino acid peptide is most widely expressed in the central and peripheral
nervous systems, playing major roles in cognitive function, feeding behavior and
cardiovascular regulation. NPY functions by activating a group of six G protein-coupled
receptors (Y1R-Y6R) of which the Y1R, Y2R and Y5R are most abundantly expressed in
humans, and have been most extensively studied (Michel, et al., 1998). In addition to
being expressed in central and peripheral tissues, NPY receptors have been reported to
be expressed in several cancers including neural crest tumors (e.g., neuroblastomas
and pheochromocytomas) and epithelial malignancies such as ovarian, prostate and
breast cancer (Kitlinska, et al., 2005; Kogner, Bjork, & Theodorsson, 1993; Korner &
Reubi, 2008; Korner, Waser, & Reubi, 2004; Magni & Motta, 2001; Reubi, Gugger,
Waser, & Schaer, 2001).
Expression of the Y1R subtype was first reported to predominate in breast
carcinomas (Reubi, et al., 2001). More recently, the expression of the Y5R was reported
in several human cell lines (Sheriff, et al., 2010), where its activation was reported to
promote cellular proliferation and migration. In support, we have shown similar
proliferative and migratory effects of Y5R activation in the 4T1 murine breast cancer cell

80

line (Medeiros, et al., 2012). Additionally, Y5R activation in 4T1 cells has been found to
stimulate an increase in VEGF expression and release in a concentration-dependent
manner (Chapter 3), providing the first evidence for NPY’s involvement in tumor
angiogenesis through this mechanism.
In spite of growing evidence suggesting a functional role of NPY on the
progression of breast cancer, to date, studies have been limited to in vitro
experimentation. Syngeneic immunocompetent mouse models display tumor cell-host
interactions and metastatic patterns that parallel those observed in cancer patients
(Prewett, et al., 1999). The 4T1 murine breast cancer cell line is a well-established
syngeneic model of breast cancer that has been used extensively to study antimetastatic and anti-angiogenic therapies (Lin, et al., 1998; Prewett, et al., 1999).
Moreover, our recent in vitro findings demonstrating expression of NPY receptors, as
well as the pro-proliferative, migratory, and angiogenic effects of NPY on 4T1 cells,
supports the use of the 4T1 model for functional in vivo studies.
In the tumor microenvironment the primary components of the sympathetic NPY
system include sympathetic nerve fibers (source of NPY), NPY, NPY receptors and
DPPIV and APP. Therefore, in the current study we sought to develop an in vivo model
in which the components of NPY system (i.e., nerves, ligands and receptors) could be
functionally studied. We first began by probing for sympathetic nerves and NPY in 4T1
tumors. In order to determine the effects of the nerves on tumor growth and vascularity,
we sought to develop a sympathetically dennervated tumor model. With our findings
demonstrating a role for the Y5R in cell growth in this model, we then tested the effects
of daily treatment with a Y5R antagonist on tumor growth. Finally, we attempted to
develop a protocol for vascular imaging in 4T1 tumors using intravital video microscopy.
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4.2 Methods
4.2.1

Reagents and Drugs
Fetal bovine serum (FBS), culture media, Hank’s Balanced Salt Solution (HBSS)

and trypsin were purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON,
Canada). For immunohistochemistry and Western blot experiments we used primary
antibodies specific to mouse tyrosine hydroxylase (Cat no. AB152, EMD Millipore
Corporation, Billerica, MA, USA), mouse NPY (Cat no. NPY11-A, Alpha Diagnostic Intl.
Inc., San Antonio, Texas, USA), Anti- α-Smooth Muscle Actin - Cy3 (Cat no. C6198,
Sigma-Aldrich Canada Ltd, Oakville, Canada), Anti-PECAM-1-FITC (Cat no. CBL1337F,
EMD Millipore Corporation, Billerica, MA, USA). For immunohistochemistry secondary
incubation we used Alexa Fluor® 594 Goat Anti-Rabbit (Cat. no. A-11012, Invitrogen
Canada Inc., Burlington, ON, Canada). For Western blots we used secondary antibody
conjugated to horseradish peroxidase (goat anti-rabbit IgG, Cat no. A0545, Sigma
Aldrich, St. Louis, MO, USA). Lysis buffer (M-PER Mammalian Protein Extraction
Reagent), protease inhibitors were purchased from Pierce (Rockford, IL, USA). 6Hydroxydopamine hydrobromide (6-OHDA) was purchased from Sigma (Cat no. H116,
Sigma Aldrich, St. Louis, MO, USA), Triphase Accelerator Corp kindly provided the NPY
Y5R antagonist TAC557 for tumor growth studies.

4.2.2

Cell Culture
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan USA),

were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM)
supplemented with 10% sterile FBS. Cells were incubated at 37ºC and 5% carbon
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dioxide. At approximately 80% confluency, cells were washed with HBSS and passaged
using 0.25% trypsin-EDTA treatment for dissociation.

4.2.3

4T1 Orthotopic Tumor Growth Characterization
BALB/c mice, purchased from Charles River Laboratories (Saint-Constant, QC,

Canada) at 6-7 weeks of age, were used for tumor growth studies. Animals were housed
in the animal care facility at The University of Western Ontario. They were maintained on
Harlan 2018, Teklad Global 18% Protein Rodent Diet and water ad libitum and kept on a
12 hour light/dark cycle. All experimental procedures were carried out with the approval
of the Council on Animal Care at The University of Western Ontario.
After three passages, 4T1 cells were prepared for injection. Cells were washed
and resuspended in sterile HBSS. The solution was filtered with a 40 µm cell strainer
and cell viability was assessed by trypan blue staining and counting with a
hemocytometer. The cell suspension was diluted to 103 cells/µl for injection.
Animals were anesthetized with isofluorine/oxygen gas mask (2-3% isofluorine, 1 L/min)
and hair was removed from the lower abdominal region using commercial hair remover
(Nair®). A sagittal cut (~1 cm) was made at the lower abdomen and skin was separated
from the underlying muscle, to expose the underlying mammary fat pad. One hundred
microliters (105 cells) of cell suspension was carefully injected into the right inguinal
mammary fat pad. Wound clips were then applied to close the skin incision. Animals
were returned to their cage for recovery and wound clips were removed 7 days later.
Animals were then housed in cages without disturbance for 29 days. Twenty-nine days
post-injection, all mice were sacrificed after induction of anesthesia using Ketamine (100
mg/kg) and Xylazine (25 mg/kg) followed by cervical dislocation. Mammary tumors were
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removed from each animal, sectioned in half, one half flash frozen in liquid nitrogen and
the other fixed in 4% paraformaldehyde.

4.2.4

Immunohistochemistry: Detection of Sympathetic Nerves
and NPY
Tumors were immersed in 4% paraformaldehyde solution in PBS, followed by

paraffin processing and tissue embedding. Tumor tissues were sectioned (5µm
thickness) and sequentially placed in triplicate on glass slides in staggered formation
(with a non-specific binding control section on each slide). Following deparaffinization,
tissues were placed in antigen retrieval buffer for 30 minutes at 75°C (10 mM sodium
citrate buffer, 0.05% Tween-20, pH=6.0), washed in PBS, and blocked and
permeabilized for 1hr in blocking solution (1.5% normal goat serum, 0.2% Triton-X 100
(in PBS)) at room temperature. Sections were incubated overnight in primary antibody
raised in rabbit specific to mouse tyrosine hydroxylase (TH) (Abcam Inc., Cambridge,
MA, 1:1000) or NPY (Cat no. NPY11-A, Alpha Diagnostic International, San Antonio, TX,
USA 1:500) diluted in 2% BSA in PBS at 4ºC. Following several washes in PBS
Tween20, tissues probed with TH were incubated in goat anti-rabbit Alexa 594 (1:2000)
and anti-mouse CD31 (PECAM-1) Fluorescein isothiocyanate conjugate (1:1000) to
stain endothelial tissue, for 1 hour at room temperature. Slides probed for NPY were
incubated in goat anti-rabbit Alexa 488 (1:2000) for 1 hour. All slides were washed and
then treated with 100µl of 4’-6’-Diamidino-2-phenylindole (DAPI) in the dark for 5
minutes. Finally, slides were then rinsed in PBS and cover-slipped with mounting
medium Vectasheild (Vector Laboratories, Burlington, ON, Canada). Images were
acquired using a Zeiss Axioplan 21E bright-field microscope (Carl Zeiss, Canada),
ZeissAxioCam Hr camera (Carl Zeiss) with AxioVision 4.6 software (Carl Zeiss).
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4.2.5

Sympathectomized 4T1 Tumor Model

Mice were anesthetized with isoflurane gas (30% isoflurane). The lower abdomen was
defurred and prepped with betadine 3 part preparation. A 1-1.5 cm linear incision was
then made along the midline to lift the skin and blunt dissection was performed to
expose the inguinal mammary fat pad. A 0.006mg/g dose of 6-OHDA or saline control
was given by injection into the inguinal mammary fat pad (100 µl). Following injection,
the incision was closed with wound clips and mice were returned to their cages,
monitored during recovery and given a dose of subcutaneous fluids. Wound clips were
removed within 3-4 days post surgery. Five days after the chemical dennervation, 4T1
mammary inoculations were conducted as earlier described. Tumors growth was tracked
for up to three weeks, after which mice were sacrificed; tumors were removed, weighed
and sectioned in half for Western blot analysis (flash frozen) and immunohistochemistry
(paraffin embedded).

4.2.5.1

Western Blot Analysis of Tumor Sympathetic Innervation

The effectiveness of 6-OHDA to ablate tumor sympathetic innervation was tested by
Western blot analysis of TH expression in tumor lysates. One hundred milligrams of
tumor tissue was immersed in ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium
chloride, 5 mM ethylene glycol tetraacetic acid, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate and 1% Triton-X 100) and mechanically homogenized. Lysates
were centrifuged for 15 minutes at 14,000 rpm at 4°C. Supernatant was collected and
stored at -80°C until protein concentration was determined.
A Bradford assay (Bradford, 1976) was performed to determine total protein
concentration of samples. Thirty-five micrograms of protein from each sample and a
positive control (brain lysate) were loaded on a 4% to 12% gradient gel and separated
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by SDS-PAGE. After electrophoresis, proteins were transferred at a constant voltage to
polyvinylidene fluoride membranes. Membranes were blocked for 1hr in 5% milk in TrisBuffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated in
primary antibody specific to mouse TH (1:1000) in 5% BSA in TTBS at 4°C overnight.
Membranes were washed in TTBS then incubated in secondary antibody conjugated to
horseradish peroxidase (goat anti-rabbit IgG, 1:20000) in 2% BSA in TTBS for 1hr.
Membranes were washed three times and bands were detected using an Immun-Star
WesternC© chemiluminescent kit (Bio-Rad, Hercules, CA, USA) and imaged with the
ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Membranes were stripped,
washed then probed for β-actin (1:5000 primary; 1:20000 secondary). Densitometric
band analysis was performed with Quantity One 1-D Analysis Software (Bio-Rad,
Hercules, CA, USA).

4.2.5.2

Immunohistochemistry: Tumor Muscular Vessel
Quantification

Tumors immersed in 4% formaldehyde in PBS were paraffin processed and paraffin
embedded. Five µm sections were, deparaffinized, then placed in antigen retrieval for 50
minutes at 70°C. Sections were washed in PBS then blocked and permeabilized at room
temperature [2% bovine serum albumin (BSA), 0.2% Triton X (in PBS)]. After a PBS
wash, tissues were incubated in primary antibody specific to mouse platelet endothelial
cell adhesion molecule (PECAM-1-FITC conjugate) and α-smooth muscle actin (α-SMArhodamine conjugate) ([PECAM-1] = 9.8µg/mL, α[α-SMA] = 4.975µg/mL] for two hours at
room temperature. After several PBS washes, sections were incubated with Sudan
Black Solution (1% in 70% ethanol) at room temperature for one hour. Then sections
were rinsed in Hank’s Buffered Salt solution and then incubated in 4’,6-diamino-2-
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phenylndole, (DAPI; 12.5µg/mL) for ten minutes, after which slides were washed and
mounted.
Images were acquired at 20X magnification using a Zeiss Axioplan 21E brightfield/fluorescence microscope (Carl Zeiss, Canada), ZeissAxioCam Hr camera (Carl
Zeiss) with AxioVision 4.6 software (Carl Zeiss). For each tumor, five random fields of
view were acquired for two sections. Muscular vessels immunoreactive for α-smooth
muscle actin were counted by a blind observer and then averaged per animal. The mean
number of muscular vessel per mm2 was calculated for the two different groups.

4.2.6

Y5R Antagonist Tumor Growth Experiments

The effects of Y5R antagonism on tumor growth were examined using the 4T1 tumor
model. Tumor cells (5x103 cells in 100µl of PBS) were implanted as previously described
in 5-6 wk old female Balb/c mice (n=28). Once tumors reached ~125-150 mm3 (day 17),
mice were randomized into 4 groups based on tumor volume and body weights (n=7 per
group). Each group received an oral daily dose (at 10 AM) of TAC557 (Trans isomer;
provided by Triphase) (~ 0.1 ml) by gavage (22G feeding needle) at one of the following
concentrations: 1) 5 mg/kg (1 mg/mL), 2) 30mg/kg (6mg/mL), 3) 90mg/kg (18mg/mL), 4)
vehicle control. TAC557 was reconstituted in 0.1%CMC (low viscosity, Sigma, Cat no.
P8074) + 0.08%tween-80 in water solution at a concentration of 30 mg/mL. The stock
solution was diluted for each respective group and stored at 4˚C for the length of the
study. Volume of drug was calculated based on animal body weight, which was
measured daily. Drug or vehicle was administered until tumor volume exceeded
1500mm3. When animals exhibited signs of distress (e.g., labored breathing, or body
weight loss > 15%) they were sacrificed. Animal weights were monitored on a daily basis
for the duration of the study. External caliper measures of tumors were taken every
second day, which were used to calculate tumor volume using the modified ellipsoid
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formula 1/2(Length × Width2). At the termination of the experiment, tumors were excised,
weighed, and then sectioned in half. One half was flash frozen and the other was
formalin fixed. Additionally, given high propensity for 4T1 cells to metastasize to the
lungs, we also removed the lungs of all mice for qualitative analysis of metastatic
lesions.

4.2.7

Intravital Video Microscopy Tumor Model
Mice were anesthetized with isoflurane gas (30% isoflurane), then placed supine

on a custom-fabricated animal platform that uses conducted heat with animal
temperature feedback to maintain esophageal temperature at 37°C. With the ventral side
of the animal shaved and skin prepped, under microscopic guidance, a sagittal cut
(~2cm) was made at the lower abdomen, and skin was carefully separated from the
underlying muscle to expose the underlying mammary tumor. As we routinely observed
vasculature and nerves originating from the femoral region, extra caution was taken to
preserve this neurovascular supply. The skin flap was then gently reflected away from
the mouse, spread evenly onto a custom-fabricated transparent Sylgard pedestal to
approximate in situ dimensions, and pinned to secure edges. The preparation was then
superfused continuously (4-5 ml/min) with a bicarbonate-buffered (pH, 7.4) physiological
saline solution (PSS) equilibrated with 5% CO2 / 95% N2 and maintained at 34-35°C at
the tissue. PSS was incubated in a thermally-jacketed 50-ml equilibration chamber
positioned above the tissue, gravity-fed by a 2-litre reservoir containing control PSS.
PSS was delivered from the chamber to the proximal edge of the tissue; effluent was
aspirated continually ensuring constant flow of fresh PSS across the tissue. This
preparation provided access to servicing tumoral vessels, surface vasculature and
neural fibers. Once the preparation was complete, a tail vein injection of a flurorescent
dextran (FITC or Rhodhamine; 0.05ml) could be administered (Varghese, et al., 2005).
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Upon completion of microsurgical procedures, the preparation was transferred to the
stage of the intravital microscope (Olympus BX51). The preparation was allowed to
equilibrate for ~30 min, during which vascular networks were scanned. Dextran-filled
vessels were excited with Mercury Vapor Short Arc light source (EXFO, X-Cite 120PC
Q). Images were captured with a front-illuminated interline CCD camera (Qimaging EXi
Blue) and viewed/collected using specialized imaging software MetaMorph 7.6. This
preparation allowed for the collection of high-resolution video of flowing microvessels
from which information regarding vessel diameter, vascular density and tortuosity could
be gathered.

4.2.8

Statistical Analysis

Data presented as mean ± SEM. The Student’s t-test was used to compare tumor mass,
TH expression and muscular vessels in control and 6-OHDA mice. A One-way ANOVA
with a Tukey post hoc test was used to compare treatment groups in the Y5R antagonist
tumor study. All statistical analyses, were performed using Prism (version 4, GraphPad
Software Inc, La Jolla, CA, USA) and differences were accepted as statistically
significant when p<0.05.

4.3 Results
4.3.1

4T1 Orthotopic Tumor Growth Characterization

The growth rate of 4T1 tumors was tracked over a 35-day period (Figure 4.1). Tumor
engraftment was successful in all 20 animals inoculated. Two weeks after tumor cell
inoculation, tumor volumes were similar in all groups (150-250mm3), by the third week of
tumor growth, we observed exponential growth of tumors in mice inoculated with 104,
1.5x104 and 2x104 cells.
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Figure 4.1 4T1 tumor growth curves. Growth rate of 4T1 tumors was tracked for up to
35 days using caliper measures. Groups of mice (n=5/group) were inoculated with
5x103, 104, 1.5x104, or 2x104 cells in the inguinal mammary fat pad.

90

4.3.2

4T1 Tumors Express Sympathetic Nerves and NPY

Sympathetic

innervation

of

the

4T1

mammary

tumors

was

confirmed

by

immunofluorescence staining of sympathetic neural varicosities (tyrosine hydroxylase) of
serial sections. We consistently observed sympathetic neural tissue that invaded deep
into tumors surrounding tumor cells and tumoral arterioles (Figure 4.2 A.). Moreover,
positive immunofluoresence revealed robust expression of NPY in 4T1 tumor sections
(Figure 4.2 B.)

A.
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B.

Figure 4.2 4T1 tumors are innervated by sympathetic nerves and express NPY. (A.)
These cross-sectioned
sectioned images (main image acquired at 16x, inset images at 63x)
illustrate sympathetic neural invasion after 29 days of tumor growth. Tyrosine
hydroxylase immunofluorescence was observed (Alexa 594
594-red)
red) in newly formed
arterioles (endothelial cells stained with CD31
CD31-FITC antibody) servicing mammary fat
pad tumors (tumor cell nuclei: DAPI
DAPI-blue). Panel B. depicts positive FITC-green
FITC
immunofluorescence
mmunofluorescence staining illustrating robust NPY expression in 4T1 breast cancer
tumors (16x, tumor cell nuclei: DAPI
DAPI-blue, NPY: FITC, scale bar: 100µm
m)
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4.3.3

Sympathetically Dennervated Tumor Model

We used 6-OHDA treatments to chemically ablate sympathetic innervation of the
inguinal mammary fat pad of mice prior to tumor cell engraftment. Treatment with 6OHDA resulted in a 55% reduction in tumor mass compared to sham-treated controls
(Figure 4.3 A.) Accordingly, TH expression was significantly reduced in 6-OHDA treated
animals (Figure 4.3 B.). Immunohistochemical analysis was used to quantify tumoral
muscular blood vessels in 6-OHDA treated and control animals. We observed a
significant reduction in the number of muscular blood vessels in tumors from 6-OHDA
treated mice compared to control (p<0.05, Figure 4.4).
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Figure 4.3 The effect of chemical sympathectomy on tumor mass. Tumor mass was
reduced by 55% in tumor
tumor-bearing mice which received 6-OHDA
OHDA mammary gland
treatment prior to tumor cell inoculation (A.). Western blot analysis of tumor lysates
revealed a reduction in TH, supporting a reduction in sympathetic inn
innerv
ervation of 6-OHDA
tumors (B.). (n=5/group, mean ± SEM, *p<0.05, t-test)
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Figure 4.4 Effect of chemical sympathectomy on tumor muscular blood vessels.
Immunofluorescence (Red; α-smooth
smooth muscle actin, Green; CD31, Blue; DAPI) was used
to quantify muscular blood vessels in control and 6
6-OHDA
OHDA tumors. Mammary gland
treatment with 6-OHDA
OHDA prior to tumor inoculation caused a 46% reduction in muscular
blood vessels in tumors compared to control tumors. 10 images per tumor were acquired
a
at 20X, and counted by a blind observer, scale bar = 100µm
m (n=4/group, mean ± SEM,
*p<0.05, t-test)
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4.3.4

The Effects of Y5R Antagonism on 4T1 Tumor Growth
This experiment was performed over 47 days. Treatment with TAC557

commenced 17 days after tumor cell inoculations; at this point all tumors were at a
volume of >100mm3. Mice received treatment for an average of 21 ± 2 days in the
control group, 22 ± 2 days in the 5mg/kg and 30 mg/kg groups and 23 ± 6 days in the 90
mg/kg group (mean ± SD). Individual tumor growth curves are depicted in Figure 4.5.
Mean tumor growth curves are represented in Figure 4.6 A. Final mean tumor volumes
were: Control: 1631 ± 106 mm3, 5mg/kg: 1316 ± 137 mm3, 30mg/kg: 1237 ± 124 mm3,
and 90 mg/kg: 1030 ± 154 mm3 (mean ± SEM, Figure 4). A significant reduction in mean
tumor mass was observed in mice treated at 90mg/kg of TAC557 compared to vehicle
treated controls. Mean tumor mass was 2.16 ± 0.25 g, 2.23 ± 0.22 g, 1.79 ± 0.25 g, and
1.32 ± 0.14 g respectively (mean ± SEM, Figure 4.6 B.). Qualitatively, we observed a
reduction in metastatic lesions in the lungs of mice treated with 90 mg/kg compared to
vehicle treated controls (Figure 4.7).
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Figure 4.5 Individual tumor growth curves of tumor
tumor-bearing
bearing mice treated with the
Y5R antagonist TAC557. Tumor bearing mice were treated daily via oral gavage with
TAC557 at one of three dosages (5mg/kg, 30mg/kg, 90mg/kg), control animals received
the drug vehicle. The
he onset of treatment commenced on day 17 (depicted by vertical
black line)
ine) and continued up to day 46. T
Treatment
reatment duration was variable due to attrition.
Tumor volumes were calculated from caliper measures made every second day. Of
note, in the 90mg/kg group
up two animals exhibited outlier tumors and were sacrificed prior
to conclusion of the study.
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Figure 4.6 Effect of Y5R antagonism on 4T1 tumor growth. Tumor bearing mice were
treated daily via oral gavage with TAC557 at one of three dosages (5mg/kg, 30mg/kg,
90mg/kg), control animals received the drug vehicle. The onset of treatment commenced
on day 17 (depicted by vertical black line) and continued up to day 46, treatment
duration was variable due tto
o attrition. Tumor volumes were calculated from caliper
measures made every second day. Mean tumor volumes are depicted in panel A. Panel
B represents final mean tumor mass for each treatment group. Treatment with TAC557
at 90mg/kg significantly attenuated tumor growth compared to vehicle treated controls
(n=7/group, *p<0.05, one
one-way ANOVA)
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Figure 4.7 Effect of Y5R antagonism on lung metastasis. Lungs were removed from
all mice for qualitative analysis of me
metastatic
tastatic lesions. As depicted in the photographs, the
highly metastatic 4T1 cells formed several lesions in the lungs of vehicle treated
controls, an effect that appeared to be attenuated in mice treated with 90mg/kg of
TAC557.
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4.3.5

Intravital Tumor Model

This preparation provided access to servicing tumoral vessels, surface vasculature and
neural fibers (Figure 4.8). Using flurorescent dextrans (FITC or Rhodamine) to label
plasma, this preparation allowed for the collection of high-resolution video of flowing
microvessels and provided images from which vessel diameter, vascular density and
tortuosity could be rendered.
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Figure 4.8 Establishing Intravital Microscopy 4T1 Model. The highly angiogenic 4T1
model is well suited for intravital optical imaging. Within one week of inoculation tumors
develop (tumor volume ~100mm3). These tumors rapidly recruit vasculature from the
skin and muscles of the femoral region. This figure illustrates that when carefully
microdissected,
odissected, the skin of the lower abdominal region can be pinned out which allows
for optical imaging of servicing vasculature, surface blood vessels and nerves using
inverted microscopy.
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4.4

Discussion

Accumulating evidence has supported a pathological role for NPY on breast
cancer progression. To date, such findings have been limited to in vitro studies. Our
group recently reported the expression of NPY receptors in the 4T1 breast cancer
model. Moreover, we have observed pro-proliferative, migratory and angiogenic effects
when 4T1 cells were exposed to NPY in vitro. As such, the impetus for the current study
was to develop an in vivo model of breast cancer in which: 1) the components of the
sympathetic NPY system could be characterized, 2) a functional role of NPY on tumor
growth could be elucidated, and 3) a protocol for vascular imaging of 4T1 tumors using
intravital video microscopy could be established. Herein, we demonstrated sympathetic
neural innervation and NPY expression in 4T1 tumors. Additionally, when tumor
sympathetic neural innervation was attenuated (via chemical sympathectomy), tumor
growth and vascular development decreased significantly. Additionally, tumor growth
was attenuated when tumor-bearing mice were treated with a Y5R antagonist. Finally,
we established a protocol for intravital microscopy imaging of tumoral vasculature.
Isolated by Dr. Fred Miller (Aslakson & Miller, 1992; Dexter, et al., 1978), the
highly aggressive and invasive 4T1 murine mammary cancer cell line represents a
syngeneic model that is highly tumorgenic, effectively metastasizes, and exhibits similar
metastatic characteristics to those clinically observed (Lin, et al., 1998; Pulaski &
Ostrand-Rosenberg, 1998, 2001). As a first step, we tracked tumor growth rates of
varying number of implanted cells. Others have reported tumor development with
implantation of as few as 5 x103 cells (Pulaski & Ostrand-Rosenberg, 1998). In our
experiments, we also observed tumor development when 5x103 cells were inoculated
into inguinal mammary fat pad. Although tumor growth curves were similar for the first 14
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days of tumor bearing, growth rates from 104, 1.5x104 and 2x104 cell engraftments
exhibited a more exponential growth profile after 21 days of tumor bearing and reached
a terminal volume (>1500mm3, as per ethical approval) by 28 days for 2x104 cells, and
35 days for 104 and 1.5x104, while tumors from 5 x103 cells engraftments were
<1000mm3. As such, for drug/therapeutic studies that require a longer tumor growth
period, engraftment of 5 x103 cells were deemed optimal.
Nerve fibers of the SNS are the primary source of NPY to peripheral tissues and
organs. Sympathetic nerves arising from the lateral and anterior cutaneous branches of
the second to sixth intercostal nerves abundantly innervate the human breast providing
the microenvironment of the breast with a constant outflow of sympathetic ligands
(Fischer & Bland, 2007). Although an increasing number of studies have examined the
effects of sympathetic neurotransmitters on cancer progression, few studies have
examined the presence and or role of the sympathetic nerves in non-neurally derived
cancers. To the best of our knowledge, in epithelial malignancies, the presence of
sympathetic nerves has only previously been reported in a rat model of tongue cancer
(Raju, Haug, Ibrahim, & Heyeraas, 2007). In the current study, we observed positive
tyrosine hydroxylase immunoreactivity, providing evidence of tumoral sympathetic
innervation, thus providing a supply of sympathetically derived neurotransmitters to
tumor cells and blood vessels. Accordingly, we observed robust positive expression of
NPY in tumors. Although, we did not colocalize TH immunoreactive nerves fibers with
NPY expression in the current study, others have demonstrated colocalization of TH and
NPY in human sympathetic neurons (Jarvi & Pelto-Huikko, 1990). Future studies should
address the localization of NPY and its origin in the tumor environment.
Sympathetic neurotransmitters can stimulate increased cell proliferation, thus it
has been hypothesized that depleting neurotransmitter supply by ablating sympathetic
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neurons may retard tumor growth. We tested this hypothesis by developing a chemically
sympathectomized breast cancer model. Mammary tumors of mice treated with 6-OHDA
prior to tumor cell implantations were 50% smaller then control animals. Similar findings
were observed using bilateral sympathectomy, which cause a significant reduction in
tongue tumors (Raju, et al., 2007). Similar effects have also been observed in a murine
skin tumor model where sympathetically dennervating the skin caused a significant
reduction in the growth of tumors (Romeo, et al., 1991),.
Tyrosine hydroxylase is expressed in all sympathetic nerves and serves as the
rate-limiting enzyme in the biosynthesis of sympathetic catecholamines (Udenfriend,
1966). Increased TH expression provides index for number of nerve fibers, as well as
increases in sympathetic nerve activity (Wong & Tank, 2007). As such, in the current
study TH expression was measured in control and 6-OHDA treated mice. A local
inguinal mammary injection of 6-OHDA was given in the current study at a concentration
which has been reported to deplete the abdominal region of sympathetic nerves for up to
35 days when administered intraperitoneally (Kvist-Reimer, Sundler, & Ahren, 2002).
Although a significant reduction in TH expression was observed in 6-OHDA mice
compared to controls, TH expression was still observed in 6-OHDA mice, indicating
some level of tumor innervation. The release of pro-neurogenic factors from tumor cells
such as nerve growth factor (NGF) may in part explain the presence of sympathetic
nerves in 6-OHDA treated mice we observed. Treatment with murine NGF was found to
reverse the tumor reducing effect of 6-OHDA in a murine neuroblastoma model (Fink &
Mirkin, 1987). Thus, in spite of initial sympathetic dennervation of the mammary gland
with 6-OHDA, elevated NGF released from 4T1 cells may have been involved in
promoting neurogenesis during tumor development.

104

Elevated angiogenic activity is obligatory to tumor development. Several factors
including sympathetic neurotransmitters interact with tumor cells and existing
vasculature to stimulate increased tumor vascular supply. Thus, we examined the effects
of sympathetic dennervation (6-OHDA) on tumor vascularity. We observed a significant
reduction in the number of muscular blood vessels in 6-OHDA tumors compared to
controls. Contrary to our findings, 6-OHDA treatment was reported to increase
angiogenesis in a melanoma tumor model (Basu, et al., 2004). However, this was
observed following systemic dose of 6-OHDA. Moreover, B16 melanoma cells have
been previously reported to express and secrete catecholamines (Freed, Adinolfi,
Laskin, & Geller, 1989), thus this tumor model may not best represent that of other
carcinomas. Furthermore, the direct effects of catacholamines of NPY on the B16 cells
were not examined in this study. In stressed mouse tumor models and pharmacological
studies, elevated catecholamines and NPY have been associated with increased
angiogenesis, supporting our findings in the current study (Kitlinska, et al., 2005; Raju, et
al., 2007; Thaker, et al., 2006; Yang, et al., 2009).
Our group and others have reported that Y5R activation stimulates breast cancer
cell proliferation (Medeiros, et al., 2012; Sheriff, et al., 2010), however these findings had
yet to be supported in vivo. Tumor-bearing mice treated with the Y5R-specific antagonist
TAC557 exhibited slowed tumor growth compared to non-treated control animals. More
remarkably, we observed a 39% reduction in tumor mass in animals receiving a daily
oral dose 90 mg/kg of TAC557. Although treatment with 5 mg/kg and 30 mg/kg initially
appeared to have a modest attenuating effect on tumor growth, final tumor measures
indicated no effect with these dosages.
From initial tumor growth experiments we determined 5x103 cells to be an ideal
number of cells to engraft, that would consistently develop tumors and provide a tumor
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bearing period long enough to test the effectiveness of TAC557. The 4T1 model is
known to spread to lungs, lymphatics, liver, brain and bone (Aslakson & Miller, 1992;
Pulaski & Ostrand-Rosenberg, 2001). We observed considerable metastatic lesions in
the lungs. Qualitatively, we observed that control animals exhibited a greater number
and size of lung lesions than animals in the 90 mg/kg. These findings were intriguing as
Y5R activation has also been implicated with increases in chemotaxis and migration of
breast cancer cells (Medeiros, et al., 2012; Sheriff, et al., 2010).
These results provide promising data supporting TAC557 as tumor suppressing
agent. Some considerations should be made for future studies when using the 4T1
model and TAC557. First, treatment commenced 17 days after engraftment once all
tumors were greater than 100 mm3. There was some variability in tumor volumes at the
onset of treatment (100-300 mm3) that may have masked more significant effects
TAC557. Given the rapid growth of 4T1 tumors, for future studies we recommend that
mice should be excluded from experimental groups if their tumors have grown beyond
an initial (pre-treatment) volume of 150mm3. This will allow for treatment to occur at a
point prior to the exponential phase of tumor growth. Based on the data from the current
study only 90 mg/kg was effective at attenuating tumor growth, therefore in future
studies, animals should be treated with higher concentrations in order to elucidate any
dose dependency of TAC557. Additionally, with such an aggressive cell line, a
combination treatment study where tumor bearing mice are treated with chemotherapy
and TAC557 may prove to augment the effects of TAC557 and increase the
translatability of this model.
Examining changes in tumor angiogenesis are most frequently conducted after
the tumor has been excised through the use of histochemical techniques. Although quite
important data can be gathered from histology such as vessel density and vessel
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morphology, the use of intravital video microscopy provides a powerful tool for acquiring
functional vascular data. In the current study we adapted intravital methodologies used
for imaging of skeletal muscle (Al-Khazraji, Novielli, Goldman, Medeiros, & Jackson,
2012; Jackson, Moore, & Segal, 2010) and applied them to the orthotopic 4T1 tumor
model. In doing so, we developed a superfused tumor preparation (i.e., controlled salt
and gas solution) in which the viability of the tumor tissue and vasculature was not
compromised, thus tumor feed vessels, surface vasculature and neural fibers could be
imaged over a period of up to 4 hrs. Using fluorescent dextrans (FITC or Rhodamine) to
label plasma, this preparation allowed for the collection of high-resolution image
sequences (at 15 frames per second) of flowing microvessels. Future post-processing
and image analyses can now be developed in order to generate vascular diameter,
density, branching, and vascular geometry data. Moreover, this model could be adapted
to collect functional data such as blood vessel perfusion, red blood cell flow and
oxygenation of red blood cells. Although Doppler ultrasound can provide similar blood
flow data, the use of our preparation would allow for such measures to be made in the
presence of vasoactive compounds in real time. Imaging tumor surface vessels is,
however, limited to tumors of volumes less than 200 mm3, larger tumors become difficult
to image because of their spherical geometry. Moreover, objective specifications limit
imaging depth thus deeper vasculature in larger tumors become challenging to image.
However, servicing vasculature from the skin and femoral region may still be accessed
and imaged in larger tumors.
Overall the 4T1 breast cancer cell line provides an easily transplanted orthotopic
breast cancer model that shares similar growth and metastatic characteristics of
aggressive human breast cancers. Given our findings characterizing the components
and function of the sympathetic of NPY system in this breast cancer model, we propose
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the 4T1 model suitable for future functional studies examining the interactions between
tumor cells, nerves, ligands and blood vessels.
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Chapter 5

5

Conclusions

5.1 Thesis Summary
The work presented herein offers several novel and important findings
contributing to the understanding the effects of NPY on the progression of breast cancer.
In support of specific hypothesis 1), in Chapter 2 we reported expression of Y1R, Y2R
and Y5Rs in 4T1 breast cancer cells and tumors. Additionally, in support of specific
hypothesis 2), we observed NPY-stimulated proliferation in the 4T1 cells, which acted
via Y5R activation signalling for phosphorylation ERK1/2. Finally, confirming specific
hypothesis 3), NPY was found to be a potent chemoattractant acting through Y2R and
Y5R activation., In Chapter 3, we tested the hypothesis that NPY would stimulate an
increase in expression and secretion of VEGF from breast cancer cells, promoting in
vitro angiogenesis. Our findings from this study revealed a novel mechanism by which
NPY may contribute to tumor angiogenesis, as NPY receptor activation of breast cancer
cells increased the expression and release of the pro-angiogeneic factor VEGF and
promoted in vitro angiogenesis.
Our in vitro findings from Chapter 2 and 3 led to the development of an in vivo
tumor model in which the components of the NPY system (nerves, ligand and receptors)
could be functionally studied in an immuno-intact model. We first demonstrated
sympathetic neural innervation and NPY expression in 4T1 tumors. In order to test
specific hypothesis 5) we developed a sympathetically dennervated tumor model using
6-OHDA. We found that tumor growth and vascular development decreased significantly
in mice with dennervated inguinal mammary fat pads. Given our findings in Chapter 2,
that demonstrated Y5R mediated increases in 4T1 cell proliferation, we tested the

112

effects of oral daily Y5R antagonist (TAC557) treatment on tumor growth. In congruence
with specific hypothesis 6), we observed a significant reduction of tumor growth in mice
treated with a TAC557. As well, treatment with TAC557 appeared to reduce metastatic
lesions in the lungs. Finally, by adapting methodologies used for imaging skeletal muscle
(Al-Khazraji, Novielli, Goldman, Medeiros, & Jackson, 2012) we developed a protocol for
optical imaging in 4T1 tumors using intravital video microscopy that would allow for
servicing tumoral vessels, surface vasculature and neural fibers to be studied.

5.2 Merit
A growing body of evidence suggests that stress-related factors may contribute
to the initiation, development and progression of breast cancer. NPY has recently been
noted as such a factor, thus studies described in this thesis sought to elucidate
mechanisms by which NPY may contribute to the disease. At present, few investigations
have addressed the functional effects of NPY on breast cells and tumors. This
dissertation provides novel evidence that NPY produces potent proliferative, migratory
and angiogenic effects on breast cancer cells.
Expression of NPY receptors has been reported in several human cancer cell
lines (Sheriff, et al., 2010), however we are the first to show NPY receptor expression in
a syngeneic 4T1 murine model of breast cancer (Medeiros, et al., 2012). This model is
highly translatable, as it exhibits similar metastatic characteristics to those clinically
observed (Lin, et al., 1998; Pulaski & Ostrand-Rosenberg, 1998, 2001). Positive Y1R,
Y2R and Y5R expression was observed in this model. Interestingly, Y2R expression
contrasts the recent report that many human breast cancer cell lines lack this receptor
(Sheriff, et al., 2010). As such, the 4T1 model may be relevant to a small subset of Y2Rexpressing human breast carcinomas; nevertheless, our findings highlight the complexity
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and heterogeneity of the NPY receptors in breast cancer. Based on the findings
presented in this dissertation, the 4T1 model enables the investigation of all three
receptors (Y1R, Y2R, and Y5R) and their influence on breast cancer tumor progression.
Functionally, in this thesis, we have observed that physiological concentrations of NPY
stimulates increases in proliferation and migration, and promotes pro-angiogeneic
responses in 4T1 cells. Moreover, our work has exposed significant implications of Y5R
activation in breast cancer.
In Chapter 2, NPY-stimulated increases in cancer cell proliferation were
mediated through Y5R activation, a response previously reported in neuroblastomas and
human breast cancer cells (Kitlinska, 2007; Sheriff, et al., 2010). In Chapter 4, we
presented the first in vivo data supporting previous in vitro findings implicating Y5R
activation in tumor growth. Tumor-bearing mice treated with the Y5R-specific antagonist
TAC557 exhibited slowed tumor growth compared to non-treated control animals. We
observed a 39% reduction in tumor mass in animals receiving a daily oral dose of
TAC557 (90 mg/kg). These findings were in congruence with our data from Chapter 2,
and provide promising support for the use of TAC557 as a tumor suppressing agent
Neuropeptides have been implicated to be involved in the development of
metastasis (Drell, et al., 2003). In Chapter 2, we observed that NPY acts as a
concentration-dependent chemoattractant, where NPY-mediated chemotaxis occurs
through Y2R and Y5R activation. Similar NPY-stimulated migration has been reported in
endothelial cells as a result of Y2R and Y5R activation (Movafagh, Hobson, Spiegel,
Kleinman, & Zukowska, 2006), and in MDA MB-231 cell by Y5R activation (Sheriff, et al.,
2010). Interestingly, in Chapter 4 we observed that tumor-bearing mice treated with the
Y5R-specific antagonist TAC557 exhibited fewer metastatic lung lesions than vehicle
treated controls (qualitative observation). These findings are quite intriguing as they
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suggest potential involvement of the Y5R in metastatic progression/development, and
further highlight the therapeutic benefits of TAC557.
Although it has been established that NPY can promote angiogenesis via its
direct effects on vascular smooth muscle and endothelial cells, the findings presented in
chapter 3 provide a novel mechanism by which NPY can promote angiogenesis in breast
cancer. The observation that Y5R activation of cancer cells increased expression and
release of the VEGF from 4T1 and MDA-MB-231 cells provides the first report that NPY
can promote a pro-angiogenic microenvironment by functioning in concert with breast
cancer cells as a paracrine system.. These results support the merit of the 4T1 cell line
as a syngenic model for in vivo investigations addressing the integrated functional
effects of NPY on breast cancer angiogenesis, growth and progression and further
support investigating the Y5R as a potential therapeutic target.
Sympathetic nerves arising from the lateral and anterior cutaneous branches of
the second to sixth intercostal nerves innervate the human breast (Fischer & Bland,
2007), providing the microenvironment of the breast with a constant supply of
sympathetic ligands. Accordingly, in Chapter 4, for the first time, we demonstrated the
presence of sympathetic nerves and NPY in an orthotopic 4T1 breast cancer model.
Additionally, we demonstrated a functional role of sympathetic nerves on tumor growth
and vascularity, by chemically attenuating sympathetic innervation of mammary fat pads.
Mammary tumors of mice treated with 6-OHDA prior to tumor cell implantations were
50% smaller then control animals. Similar effects of sympathectomy have been reported
in tongue (Raju, Haug, Ibrahim, & Heyeraas, 2007) and skin tumors (Romeo, et al.,
1991). We also observed a significant reduction in the number of muscular blood vessels
in 6-OHDA tumors compared to controls. These findings highlight a role for sympathetic
nerves, catecholamines and neuropeptides in tumor growth and angiogenesis.
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Functional data from Chapters 2, 3 and 4 served as impetus for developing the in
vivo orthotopic intravital tumor model described in Chapter 4. The use of intravital video
microscopy provides a powerful tool for acquiring functional vascular data, which cannot
be acquired using histological techniques. A protocol was developed by adapting
intravital methodologies used for imaging of skeletal muscle (Al-Khazraji, et al., 2012) to
the orthotopic 4T1 tumor model. In doing so, we have now established a physiologically
viable superfused tumor preparation in which tumor feed vessels, surface vasculature
and neural fibers can be imaged under physiological in situ conditions. Overall, this
model can be used to collect valuable real-time hemodynamic data such as overall
tumor perfusion, microvascular blood flow and red blood cell oxygenation, functional
vascular density, and vessel tortuosity.

5.3 Limitations and Assumptions
5.3.1

Chapter 2
Experiments within this thesis have been primarily conducted using the 4T1

murine breast cancer model, and as such, the translatability of our findings to the human
condition could be considered limited. However, syngenic models are commonly
described as basic tools for translational research as they represent a more
physiologically complete model. Often tumor and metastatic development of human cell
xenograft models in immunocompromised mice are quite variable and sometimes
unpredictable (Bibby, 2004; Eccles, Box, Court, Sandle, & Dean, 1994). Unlike human
cell xenograft models, the 4T1 model provides an immuno-intact environment, and given
the cross-talk between the immune system and SNS, the 4T1 model represents a
physiologically relevant breast cancer model in which nerves, ligands, tumor cells and
blood vessels can be studied.
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Positive Y2R expression in the 4T1 model contrasts the recent report that many
human breast cancer cell lines lack this receptor (Sheriff, et al., 2010). Based on the
work of others (Reubi, Gugger, Waser, & Schaer, 2001), we acknowledge that the Y2R
effects observed in our work may be relevant to a small subset of human breast
carcinomas. However, our current findings highlight the complexity and heterogeneity of
the NPY system in breast cancer. Thus, this model enables the investigation of all three
receptors (Y1R, Y2R, and Y5R) and their influence on breast cancer tumor progression.

5.3.2

Chapter 3
The objective of Chapter 3 was to examine the effects of NPY on VEGF

expression and release from breast cancer cells. Although we determined that NPY
functions as a paracrine system with cancer cells to promote angiogenesis by increasing
VEGF expression and secretion, we did not test whether other pro-angiogenic factors
respond similarly. It is possible that expression and secretion of factors such as IL-6,
FGF, Ang1, Ang2, PDGF and MMP, could also be stimulated by NPY receptor
activation. Additionally, expression and release of such factors could be dependent on
receptor subtype-specific interactions. Functional experiments in this study were limited
to in vitro angiogenesis assays, thus recapitulating similar NPY-mediated effects in vivo
would strengthen and increase the impact of findings reported in Chapter 3.

5.3.3

Chapter 4
In Chapter 4 we sought to develop an in vivo model in which the components of

the NPY system (i.e., nerves, ligands and receptors) could be studied functionally. The
presence of these components in 4T1 tumors was comfirmed by positive TH and NPY
immunoreactivity. Although experiments we not conducted to confirm that TH
immunoreactive nerves fibers were colocalized with NPY, others have reported a
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positive correlation between TH and NPY in human sympathetic neurons (Jarvi & PeltoHuikko, 1990). In this chapter we also developed a sympathetically dennervated tumor
model using 6-OHDA in order to determine the effects of the nerves on tumor growth
and vascularity. Although we did find 6-OHDA treatments caused a reduction in tumor
growth and vascularity, we cannot definitively conclude that it was due to a reduction in
sympathetic neurotransmitters, as these were not quantified in the study. Reductions in
TH expression of 6-OHDA tumors do however support a reduction in neurotransmitters.
Additionally, although not the objective of this thesis, throughout our experiments we did
not examine the effects of NE on proliferation, migration or angiogenesis. As such, we
cannot rule out NE as a potential mediator of the findings in the 6-OHDA model.
In Chapter 4 we tested the effects of an orally administered Y5R antagonist (TAC557) on
tumor growth. Although TAC557 exhibited promising tumor suppressing properties, we
found that only a dose of 90 mg/kg was effective at attenuating tumor growth, thus from
this study we could not conclude dose dependency of TAC557. Future studies are
required to elucidate to peak tolerable dosing and any dose dependency effects.
Additionally, because 4T1 cells are known to spread to the lungs (Aslakson & Miller,
1992; Pulaski & Ostrand-Rosenberg, 2001), we also qualitatively examined lung
metastatic burden in this study. Although the impetus for the TAC557 study was to test it
as a tumor suppressing therapy, we were quite intrigued by clear differences in lung
metastatic lesions between control and TAC557 treated mice. These findings certainly
merit subsequent studies designed to test the effects on TAC557 on metastasis.

5.4 Future Directions
Breast cancer remains the most frequently diagnosed cancer among females,
affecting thousands of women each year. Although extensive research has reduced
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death rates significantly over the past thirty years, many of the underlying mechanisms
that drive the progression of this disease remain to be defined. Stress and stress-related
factors have long been thought to be associated with the development and progression
of cancer, as epidemiological studies have correlated elevated stress with poor
prognosis and/or survival of cancer patients (Ben-Eliyahu, 2003). Accumulating evidence
suggests a pathological role for sympathetically released neurotransmitters, as their
influences increase in the response to stress and they exhibit deleterious mitogenic,
chemotaxic and angiogenic properties on cancer cells (Cole & Sood, 2012; Ruscica,
Dozio, Motta, & Magni, 2007). Expression of NPY receptors in several breast cancer
cells (Korner & Reubi, 2007; Medeiros, et al., 2012; Sheriff, et al., 2010) and a neural
supply of NPY to the breast has prompted the study of NPY as an endogenous
pathological factor, contributing to the progression of breast cancer. Overall, this
dissertation provides evidence that NPY elicits proliferative, migratory and angiogenic
effects on breast cancer cells, and describes a viable in vivo model for functional studies
examining the relationship between sympathetic nerves, neurotransmitters, cancer cells
and blood vessels on tumor progression.
The work described herein provides the foundation and impetus for several future
studies. For example, using qPCR, we recently found NPY and TH mRNA transcripts in
4T1 cells. Although not uncommon in neurally-derived cancers, to our knowledge such
an intriguing finding has yet to be reported in any type of breast cancer. Whether mRNA
transcripts for NPY and TH will translate to expression and release of NPY and NE
remains to be tested. Such a finding would lead to several interesting questions
regarding a potential NPY/NE autocrine system in the 4T1 model. Additionally, as
previously mentioned, we did not explore the effects of NE on 4T1 cells, and whether NE
or any other sympathetic neurotransmitter has any effects on 4T1 cells and tumors
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remains to be addressed. Furthermore, since NE and NPY have been shown to act
synergistically, an additional question to be asked is whether NE and NPY (or other
neurotransmitters) exert any synergistic or antagonistic effects on 4T1 cells. The
expression of multiple NPY receptors in 4T1 cells and other breast cancer cells also
highlights the potential role for the proteolytic enzymes DPPIV and APP in tumor
progression. Differences in their proteolytic activity on NPY would promote changes in
the availability or NPY2-36, or NPY3-36 (which have affinity for Y2R and Y5R) and may
impact cell proliferation, migration, and angiogenesis.
We have shown the presence of sympathetic nerves in 4T1 tumors; however,
how these nerves develop, and if they function as normal peripheral sympathetic nerves
are important questions to be addressed. Measuring sympathetic nerve output to
mammary tumors would provide valuable functional insight on the neural contribution to
tumor development. Additionally, testing whether neural development is obligatory or
potentiates a greater angiogenic response could reveal potential therapeutic targets
such as NGF neutralizing antibodies.
In breast cancer, as in other cancers, the primary tumor is often treatable; it is the
spread of cancer cells from the primary tumor to secondary sites that accounts for the
majority of cancer fatalities. Although we did find some data that would implicate a role
for NPY in metastasis, many questions remain, such as testing the involvement of NPY
(and other neurotransmitters) at all steps of the metastatic cascade (invasion,
intravasation, circulation, arrest and extravasation). In Chapter 2 we showed that NPY
exherted chemotactic effects on 4T1 cells. Thus, a question of particular interest and
clinical significance would be; Do NPY receptor-expressing cancer cells extravasate to
sites of high sympathetic innervation and neurotransmitter supply? (i.e. lymphatics or
brain).
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Finally, sympathetic neurotransmitters are acutely and chronically modulated by
stressful insults (physical, emotional, psychological, physiological), thus a few groups
have examined the role of different types of stress on tumor progression and metastasis,
however much remains to be understood. The 4T1 model represents an immunecompetent model in which the effects of both deleterious (i.e psychological) or beneficial
(i.e exercise) stress paradigms could be examined on tumor progression/ metastasis.
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